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Cancer – assessing the impact of weekly anatomical changes 
in Intensity Modulated Radiation Therapy 
 
Farhannah Aly 
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Abstract 
 
The treatment of mucosal Head and Neck (H+N) cancers with radiotherapy has seen considerable 
technological development over recent years; from large non-conformal fields, to three-
Dimensional Conformal Radiation Therapy (3-D CRT) and subsequently the introduction of 
Intensity Modulated Radiation Therapy (IMRT), Volumetric Modulated Arc Therapy (VMAT) and 
other radiation therapy delivery techniques, such as proton therapy. When compared to older 
“conventional” techniques, the IMRT planning process results in improved dose to tumour volumes, 
whilst simultaneously reducing Organ at Risk (OAR) dose; i.e. an improvement of the therapeutic 
index. This dosimetric improvement translates into clinical benefits; especially in terms of reduced 
radiotherapy toxicity and Quality of Life.  
Whilst IMRT may deliver highly conformal, high dose Radiation Therapy (RT); morphological 
variations in normal tissue and tumour anatomy occur during the course of RT. These variations 
can result in inadequate dose delivery, requiring reoptimisation of the IMRT plan. Adaptive 
Radiation Therapy (ART) is an approach whereby the treatment plan is modified to account for 
xvi 
 
these changes in patient anatomy. There is no consensus as to the optimal timing, method or 
frequency of an ART approach; as well as identifying the patients who may derive the most benefit.   
This thesis describes a prospective investigation of weekly Computed Tomography (CT) scanning 
and plan adaptation if tumour or OAR coverage was unacceptable.  The anatomical changes 
occurring in tumour and normal tissues during radiotherapy, and the subsequent effect on dose 
delivery, are quantified. The impact of plan adaptation on subsequent dose delivery is examined.  
Tumour volumes reduced in volume over the treatment period. At the end of treatment, the nodal 
volume demonstrated greater volume reduction (44 %) compared to the primary tumour volume 
(25 %), and the parotid and submandibular glands showed a volume reduction of 28 % and 26 % 
respectively. Whilst the whole parotid gland did not demonstrate a significant displacement; a 
medial shift of the lateral portion of the gland was demonstrated.  A superior displacement of the 
submandibular glands was also observed. 
Inadequate Planning Target Volume (PTV) coverage was demonstrated in 80 % of the patient 
cohort, requiring one or more adaptations of the IMRT plan during the course of treatment. In all 
cases, IMRT plan adaptation was required due to inadequate PTV coverage, rather than excessive 
OAR dose with 41 % of replanning events occurring at or before fraction 10; demonstrating that 
inadequate IMRT plan dosimetry can occur early in the treatment course. Adaptation of the IMRT 
plan led to a significant improvement in PTV coverage, as well as reduced dose to the parotid glands 
and spinal cord. 
Due to the small cohort of patients, this investigation is regarded as an exploratory study. However, 
the findings add to the literature supporting the use of an ART protocol for Head and Neck Cancer 
(HNC) patients.  Implementation of a clinical ART protocol should include imaging, contouring 
volumes on new anatomy and dose calculation within the first 10 fractions.  Further imaging and 
assessment of dose delivery should be undertaken at multiple time points during the course of 
Radiation Therapy (RT); as often as departmental resources allow.  
Significant resources are required to implement an ART strategy for all HNC patients. Identifying 
those patients who would most benefit from ART remains challenging. No recommendation can be 
made for selecting patients at highest risk for inadequate dose delivery; however patients with a 
large initial volume of nodal disease should be considered for more frequent imaging and plan 
assessment. Streamlining the ART process may also result in a more practical ART strategy; for 
xvii 
 
example the utilization of dose calculation on Cone Beam CT Imaging, and in particular automated 
contour propagation. 
Whilst a benefit of ART in terms of dose distribution has been demonstrated in this investigation; 
larger prospective studies are required to establish whether a dosimetric benefit translates into an 
advantage in terms of clinical outcome.  Ultimately, an ART strategy would only be worthwhile if it 
results in an improvement in patient clinical outcomes.   
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Chapter 1 
 
Introduction  
 
1.1 Introduction 
 
Head and neck cancer (HNC) is the eighth most commonly diagnosed cancer in Australia, with an 
estimated age-standardised incidence rate of 17 cases per 100,000 population. Of the 4409 new 
cases of HNC diagnosed in 2013, 72 % of them occurred in males. The age-standardised mortality 
from HNC in Australia in 2014 was 3.8 per 100,000 population; translating to 1040 deaths in that 
year (1). 
The treatment of mucosal HNC with radiotherapy has seen considerable technological development 
over recent years; from large non-conformal fields, to 3-D CRT and subsequently the introduction of 
IMRT, VMAT and other radiation therapy delivery techniques, such as proton therapy. This has 
been possible due to the introduction of CT imaging in the treatment planning process, combined 
with inverse planning and beam modulation; allowing for tighter sculpting of dose around the 
target volume and improved avoidance of certain organs at risk (2). This dose sculpting leads to 
steep dose gradients in anatomical regions where the tumour target volume (TV) and OARs are in 
close proximity. Due to the presence of these steep dose gradients, set-up error and anatomical 
changes during the course of radiation therapy may result in larger dose inaccuracy within tumour 
volumes and organs at risk. Image Guided Radiation Therapy (IGRT) however, improves the 
precision of radiation dose delivery (3), and daily image guidance with either kilovoltage or 
megavoltage imaging is employed with all modern radiation delivery techniques to reduce the 
impact of  interfractional variation.  
When compared to older “conventional” techniques, the IMRT planning process results in improved 
dose to tumour volumes, whilst simultaneously reducing OAR dose (3,4); i.e. an improvement of the 
therapeutic index. This dosimetric improvement has resulted in clinical benefits; especially in terms 
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of reduced radiotherapy toxicity (4,5). Prospective randomised controlled studies (6,7) and case 
series (4,8) have demonstrated reduced parotid gland toxicity using an IMRT technique, in terms of 
xerostomia incidence, salivary function recovery and Quality of Life, compared to conventional 
radiotherapy. Similarly, case series report an improved overall survival and disease free survival 
(though no locoregional control improvement) when comparing IMRT with the 3D-CRT technique 
in various head and neck tumour sites (4,9). 
Patients undergoing radiotherapy for HNC experience morphological changes during the course of 
treatment due to weight loss, tumour mass change, variations in organs at risk (e.g. parotid glands), 
reduction in muscle and fat volume and tissue oedema (3,10–14). Figure 1.1 demonstrates the 
external contour change seen in one patient 20 fractions into a 35 fraction treatment. Figure 1.2 
shows PTV contour volume reduction by fraction 20, predominantly due to shrinkage of large 
lymph nodes in the right side of the neck. On clinical examination, the tumour mass had reduced in 
size and the patient had also lost weight. The resulting external contour reduction led to the 
thermoplastic immobilisation mask becoming too loose, as well as inadequate dose delivery, 
requiring adaptation of the IMRT plan. 
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Figure 1.1. Transverse CT slice demonstrating the external contour shrinkage after 20 fractions of 
IMRT in a patient being treated for H+N cancer. This patient had large pathological lymph nodes in 
the right side of the neck, which rapidly reduced in size within the first 20 fractions of treatment; 
resulting in a immobilisation mask that became too loose for treatment. (a)- bolus at planning 
stage; (b)- bolus at fraction 20. Red double-headed arrow- demonstrates the shrinkage of external 
contour at fraction 20. 
a 
b 
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Figure 1.2. Transverse, coronal and sagittal slices of patient (whose external contour is shown in 
figure 1.1), demonstrating reduction in PTV volume at fraction 20. Green- PTV at fraction 0; Red- 
PTV at fraction 20; Light blue- spinal canal. The PTV lines have not been adjusted to within skin 
surface in this example, but are adjusted for IMRT planning purposes. 
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Whilst IMRT may deliver highly conformal, high dose RT; morphological variations in normal tissue 
and tumour anatomy which occur during the course of RT, are not specifically accounted for when 
generating the IMRT plan, since the planned dose distributions are obtained from a single planning 
CT dataset obtained approximately one to two weeks prior to the start of treatment. In addition, 
during the IMRT planning process, the deliberate placement of areas of steep dose gradient in 
patient tissue where Planning Target Volumes and Organs at Risk are in close proximity, results in a 
dose distribution which is sensitive to small changes in patient anatomy (15). Adaptive Radiation 
Therapy is an approach whereby the treatment plan may be modified during a course of RT to 
account for such changes in patient anatomy. If ART is employed when the patient thermoplastic 
immobilisation mask is noted to be loose or when clinical examination finds that enlarged tumour 
volumes have shrunk, there is a risk that ART occurs later than when it may have been initially 
required. More subtle anatomical changes, resulting in inadequate dose deposition, may occur 
earlier and may not be detected by clinical evaluation alone, an example of which is shown in Figure 
1.3. 
This thesis is an investigation of the anatomical changes occurring in tumour and normal tissues 
during radiotherapy; and the subsequent effect on dose delivery. The impact of introducing an ART 
protocol on dose delivery is also reported. 
 
  
6 
 
 
 
Figure 1.3. a) Transverse, b) sagittal and c) coronal views of a patient CT scan at planning and mid-
treatment, demonstrating subtle changes in external contour (circled) which would be undetectable 
on clinical assessment.  
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1.2 Project Aims 
 
With the widespread introduction of IMRT in the treatment of HNC, the clinical focus has been on 
improving the therapeutic window by better delineation of structures and reduction of movement 
uncertainties. Questions relating to changes in structures over the course of therapy have not been 
addressed until more recently in the radiation oncology and medical physics literature. 
Aim 1. Investigate and quantify the anatomical changes occurring in patients during HNC 
radiotherapy. 
Research questions: 
a. What volumetric changes are observed in the Target Volumes during HNC IMRT? 
b. What volumetric and geometric changes are observed in the parotid and submandibular 
glands during HNC IMRT? 
c. Are any changes in subcutaneous fat volume detectable during HNC IMRT? 
Aim 2. To investigate the impact of anatomical changes on dose delivery to the Target Volume, 
parotid glands (PG) and spinal canal; and the impact of IMRT plan adaptation on subsequent dose 
delivery to these structures. 
Research questions: 
a. What doses are delivered to the PTVs, PGs and spinal canal during unadapted HNC 
IMRT? 
b. What is the impact of plan adaptation on the PTV dose, PG dose and spinal canal dose? 
c. Do any factors correlate as predictors of when the IMRT plan requires an adaptation? 
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1.3 Chapter Overview 
 
Literature relevant to this investigation is explored in Chapter 2. The methodology, details of 
statistical analysis and details of the ART protocol employed are presented in Chapter 3.   
Chapters 4 to 6 focus on presenting the results. General results, regarding the frequency and timing 
of plan adaptations, as well as changes in patient weight and nutritional status are conveyed in 
Chapter 4. The exploration of weight and nutritional score, as correlates for unacceptable dose 
delivery are also discussed in Chapter 4. Chapter 5 describes the volumetric changes occurring in 
the various Target Volumes during H+N IMRT. The PTV, Clinical Target Volume (CTV) and Gross 
Tumour Volume (GTV) volume changes are quantified and significant trends described. The 
volumetric and geometric changes occurring in the parotid and submandibular glands are 
presented. This chapter also describes the change in fat volume within the head and neck region, 
looking at the volume differences across a range of CT slices. Chapter 6 describes the dosimetric 
changes occurring in both unadapted and adapted treatment plans, as quantified on the weekly CT 
imaging.  
Chapter 7 summarises the research findings, with a discussion on issues arising from this 
investigation. Recommendations derived from this investigation are also presented in this chapter. 
Suggestions for future research are explored at the end of chapter 7. 
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Chapter 2 
 
Literature Review  
 
2.1 Changes in Patient Weight Occurring during Radiotherapy 
for Head and Neck Cancer 
 
Patients can experience weight loss during their cancer journey, due to a multitude of reasons 
(16,17),  including: 
i. Reduction in appetite; which can occur as a result of treatment side effects, but also due to 
anxiety,  stress and fatigue.  
ii. Reduction in nutritional intake due to tumour effects; including pain, difficulty chewing or 
swallowing and cancer cachexia. 
iii. Reduction in nutritional intake due to treatment side effects; including mucositis, nausea, 
difficulty with swallowing, pain, taste and smell aversion.  
iv. Fatigue; which impacts the ability to purchase and prepare food. 
The average reported weight loss in patients, undergoing radiation therapy for HNC, ranges 
between 6 to 11 % (10,18–30).  
 
2.2 Anatomical Changes in Tumour Volumes Occurring during 
Radiotherapy for Head and Neck Cancer 
 
Tumour volumes have been shown to reduce in size during the course of radiation therapy. 
Quantifying the extent of TV reduction is challenging from existing literature, as investigators 
report volume changes in different target volumes; with volume changes described in the GTV 
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(nodal or primary or combined) (10,12,18–20,25,27,29,31–37), CTV (high or low 
dose)(11,12,23,27,29,36–41) or PTV (high or low dose) (20,27,29,36,42). In addition, the time 
points at which volume changes are reported also vary significantly; at any point from the first half 
of RT treatment and until the end of RT.  
It should also be kept in mind that volume change of the primary tumour GTV may be difficult to 
measure accurately using CT imaging, as the border of the primary tumour GTV may be difficult to 
determine on subsequent CT scans (and especially in the absence of intravenous contrast use). 
Castadot et al (12), performed CT scans with intravenous (i.v.) contrast as well as Positron 
Emission Tomography (PET) scans to investigate changes in tumour volumes and organs at risk 
during the course of RT. The use of i.v. contrast allowed for the delineation of tumour volumes with 
greater accuracy. The GTV volumes were delineated manually at each per-treatment scan; whilst 
the CTV volumes were generated using deformable image registration, with autosegmentation and 
manual correction if required. They report, at the end of treatment, a significant daily reduction of 
3.2 % for the GTV primary tumour volume, 2.2 % for the GTV nodal volume and 2.4 % for the high 
dose CTV volume. The low dose CTV volume demonstrated a non-significant daily volume reduction 
of 0.7 %.  
In two studies investigating changes in primary tumour GTV volumes and surrounding tissues 
using MRI scanning, the authors report a reduction in primary tumour GTV of 70 % and 84 % at the 
end of treatment (37,43). This is similar to reports from numerous CT studies, where GTV reduction 
in volume has ranged between 66 % and 80 % at the end of treatment (10,25,32). However, one 
study reports a much smaller GTV volume reduction of 17% at the end of treatment (18). 
The initial tumour volume may also affect the extent of volume reduction during treatment. Barker 
et al (10) report that larger initial GTVs demonstrate a faster rate of volume loss than smaller GTVs; 
whilst Wang et al (24) demonstrated that the absolute volume reduction is greater for larger lymph 
nodes.  
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2.3 Anatomical Changes in Organs At Risk Occurring during 
Radiotherapy for Head and Neck Cancer 
 
2.3.1 Parotid Gland 
 
During H+N RT, one or both of the parotid glands are generally adjacent to the high dose PTV. 
Portions of the parotid gland may even fall within the high dose PTV, as the PTV is a geometric 
construct created by adding an expansion margin to CTV volumes (which may abut the parotid 
gland). During IMRT treatment planning, dose to one or both parotid glands is a highly weighted 
dose objective.  This is because irradiation of the parotid glands leads to short and long-term 
toxicity in the form of xerostomia; which can lead to other health impacts (discussed in further 
detail in section 2.6).  
Therefore the anatomical changes occurring to the parotid gland during treatment for HNC have 
been frequently reported. The parotid glands experience a reduction in volume. When measured at 
the end of treatment, investigators report an average total volume reduction of between 21 to 59 % 
(10,18,21–23,25,30,32,37,38,41,44–46). Some of these studies utilised Cone Beam CT (CBCT) 
imaging for their analysis (21,39,44,46,47), others imaged with planning CT scans. The review 
article by Brouwer et al (48),  pooling data from multiple studies, reports an average volume 
reduction of 26  11 % in the parotid glands by the end of radiation therapy. Other investigators 
have reported daily volume reductions of 0.6 to 1.5 % (10,12,47,49) or weekly reductions of  1.7 to 
7.9 % (25,32,37,38,50).  
The parotid glands appear to experience greater volume loss in the first half of the 35 fraction 
treatment period; Wang et al (45) report a 20 % volume loss in the first half of treatment and a 11 
% volume loss in the second half of treatment; Ahn et al (18) report that the rate of volume loss 
stabilized by fraction 22; other authors (25,30,44,51) report that the glands experience a greater 
volume loss in the first half of treatment; Sanguineti et al (28) report that 60 % of total parotid 
gland volume loss occurs in the first half of treatment; and Bhide et al (11) report the largest 
parotid gland volume reduction of 14.7 % occurred between week 0 and 2. 
Some investigators have reported the ipsilateral (or irradiated) versus contralateral (or spared) 
parotid gland volume reduction in those patients with well-lateralised tumours. It is generally 
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accepted that the ipsilateral gland demonstrates greater volume reduction than the contralateral 
gland (12,20–22,34,35,39,41,52,53), as the spared gland would receive a lower dose; however 
Fiorentino et al (47) report similar volume loss for both ipsilateral and contralateral glands.  In 
addition, the parotid gland volume may be affected by pre-chemotherapy hydration (54), therefore 
it may be important to perform imaging studies at a consistent time with respect to chemotherapy 
delivery.  
The geometric movements of parotid glands have also been measured by numerous investigators. 
This has been measured by calculating the shift of the centre of mass of the entire gland (10–
12,24,52), or it’s medial and lateral edges (24,30,32,33,50), in relation to a reference point. Others 
have also measured the distance between the centre of mass of the right and left parotid glands 
(26,44), to determine if they move closer to each other (i.e. displace medially). Regardless of the 
measurement method used, a medial displacement of the parotid glands has been demonstrated 
during the course of radiation therapy (10–12,25,26,30,33,44,48,52,55); with Barker et al (10) 
reporting a 3.1 mm, and Castadot et al (12) reporting a 3.4 mm mean medial displacement at the 
end of radiation therapy. Two investigators (26,44) report a reduction in the distances between the 
centre of mass of the right and left parotid glands, indicating a medial displacement of the glands; 
by a mean of 4.9 to 5.2 mm. Jensen at al (52) stated that parotid glands displaced cranially and 
dorsally, as well as medially, however the magnitude of this displacement has not been reported by 
them. 
This shift is most likely due a displacement of the lateral portion of the gland (where the main mass 
of the gland is situated); rather than the medial portion. Marzi et al (32) report that the lateral 
aspect of the parotid gland showed a medial displacement of 6.5 4.7 mm, whereas the medial edge 
had only a 0.8 5.1 mm medial displacement. Similarly, Vásquez-Osorio et al (34) report the lateral 
portion of the gland demonstrating a significant 33 mm medial shift, compared to a 13 mm 
medial shift of the medial portion; and Other authors also report that the lateral, but not medial, 
portions displace medially (24,30,50).  The fact that the lateral portion of the parotid gland shows 
greater medial displacement than the medial portion, would suggest that most of the volume loss of 
the parotid glands described above would be occurring in the lateral potion of the gland; a view 
which is also supported by Robar et al (50).  
Similar to their finding relating to parotid gland volume,  Kagar at al (54) report that parotid gland 
displacement may also be affected by pre-chemotherapy hydration, with a lateral displacement 
seen in the immediate days following chemotherapy administration and a medial displacement 
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observed thereafter. This highlights the importance of consistent timing of imaging studies with 
respect to chemotherapy delivery. Additionally, the displacement direction and magnitude may 
vary due to set-up uncertainties and varying magnitudes of displacement in varying directions in 
different patients.  
 
2.3.2 Submandibular Gland 
 
There is less reporting of changes to submandibular gland volume and position during the course of 
radiation therapy. This is most likely due to the fact that both submandibular glands are usually 
within the high dose region and therefore it is often not possible to spare appreciable dose to these 
glands during treatment planning. However, the submandibular glands are responsible for much of 
the resting (unstimulated) salivary function (56) and where possible should be spared (without 
impacting on tumour coverage) in order to reduce later complications. 
Brouwer et al (48) reports an average volume reduction of 22 %, when combining the results of 
several studies. A reduction of volume between 11 and 37 % has been reported in other 
publications (19,22,34,45). Vásquez-Osorio et al (34) report an 11 % reduction in contralateral (or 
spared glands), smaller than a 20 % reduction for ipsilateral (or irradiated) glands; Castadot et al 
(12) report a similar finding with regards to ipsilateral and contralateral glands. Wang et al (45) 
demonstrate that there is a greater volume loss in the first half of treatment (11 %) compared to 
the second half of treatment (6 %). 
The submandibular glands demonstrate a general superior displacement during the course of 
radiation therapy of 3 to 4 mm (48). The ipsilateral gland demonstrated a greater magnitude of 
shift than the contralateral gland; with Castadot et al reporting a mean 2.7 mm and 1.7 mm shift for 
the ipsilateral and contralateral glands respectively (12). The authors also noted that the ipsilateral 
gland also demonstrated as medial displacement of 1.7 mm. Similarly, Vásquez-Osorio et al (34) 
report that the ipsilateral glands demonstrate a larger superior displacement, of 3 to 4 mm, than 
the contralateral glands, 1 to 2 mm.  
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2.3.3 Swallowing Structures 
 
Cozzolino et al (46) report a 13 % increase in larynx volume during postoperative radiation 
therapy. Similarly, Ricchetti et al (22) report significant volume increase of the constrictor muscles 
and larynx at the end of radiation therapy, due to oedema in these structures; whereas other 
muscles and the thyroid gland exhibited a reduction in volume.  Similar findings have been reported 
by Brouwer et al in their review paper (48). In an MRI-imaging study, Popovtzer et al (57) report 
volume increase in the pharyngeal constrictor muscles, due to oedema, especially in areas that 
received >50 Gy of dose. Changes in the swallowing structures were not specifically investigated in 
this study. 
 
2.3.4 The Neck 
 
Whilst the external contour of the “neck” is not considered an organ at risk; the anatomical change 
in neck contour is of interest, as it would be affected by weight loss, muscle atrophy and tumour 
mass reduction. A reduction in volume within the external skin contour has been reported during 
radiation therapy (10,19,42), the extent of which correlates with the weight loss in the patient 
(10,19). Another method of evaluating changes in the “neck” has been to quantify the transverse 
neck diameter, or skin separation; this parameter also shows a reduction in size during radiation 
therapy (18,24,27,38) and similarly shows a correlation with weight loss. 
 
2.4 Dosimetric Changes to Tumour Volumes Occurring during 
Radiotherapy for Head and Neck Cancer 
 
Section 2.2 reviews the volume changes occurring in the delineated tumour volumes (GTV, CTV, 
PTV) during radiation therapy. These changes would be expected to alter the dose distribution to 
the tumour target volumes from what has been planned; with inadequate dose delivery potentially 
compromising tumour control probability. There is variability in reporting of dose to tumour 
volumes; with some investigators reporting dose to PTV and others to CTVs or GTVs. Additionally, 
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the Dose-Volume Histogram (DVH) measures quantified also varies; e.g. V98 (Volume receiving ≥98 
% of the prescription dose), V95 (Volume receiving ≥95 % of the prescription dose) and minimum 
dose are some measures reported. This makes it challenging to directly compare studies.  
In terms of PTV coverage, some investigators report a reduction in dose to the PTV structures 
during the course of radiation therapy (11,18,29,42,53). Reduced dose homogeneity within the PTV 
is also reported (11,18,20,29). Other investigators, however, report that the PTV is not significantly 
underdosed (20,24–26,40). Castadot et al (58) report a 2 Gy dose reduction to the high dose PTV, 
but the low dose PTV experiences <0.2 Gy reduction. Ahn et al (18) report reduced coverage of the 
PTV of the nodal region, but not the PTV of the primary tumour. 
Zhao et al (35) and Zhang et al (41) report underdosing of the CTV volume during the RT course, 
however other investigators report that the CTV is not underdosed as a result of the anatomical 
changes occurring (23,37,40,46,58,59). The GTV is not underdosed during the course of RT 
(31,32,59); which seems logical, as the GTV is the smallest volume which tends to reduce in size, 
and from which the CTV and subsequently PTV are constructed, and therefore would be least 
affected by anatomical variations.  
 
2.5 Dosimetric Changes in Organs At Risk Occurring during 
Radiotherapy for Head and Neck Cancer 
 
2.5.1 Parotid Gland 
 
In section 2.3.1, volume loss and medial displacement of parotid glands have been discussed. IMRT 
planning functions to sculpt the dose around the parotid glands in order to reduce dose to the gland 
whilst maintaining tumour dose coverage; as the parotid glands and PTV volumes are in close 
proximity and may even overlap. Medial displacement potentially moves the parotid glands into the 
high dose region, with dose delivery differing to what was originally planned. 
Different measures are used to report parotid gland dosimetry, including mean dose, V26 (Volume 
receiving ≥26 Gy), V30 (Volume receiving ≥30 Gy) and D10 (minimum dose to 10 % of the volume); 
however the most commonly used metric is the mean dose. In addition, dose to the parotid glands 
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is measured at various time points of radiation therapy. The literature consistently demonstrates 
that the parotid glands receive a higher dose than was originally planned; this ranges from 0.92 to 
5.6 Gy increase in dose in different papers (11,18,20,24–26,29,32,33,38,40,41,44,46,53,60,61). 
Brouwer et al (48), in reviewing multiple papers report the average increase in mean dose during 
radiation therapy as 2.2 2.6 Gy. A dose increase occurs early in the treatment course; with 
significant changes occurring from fractions 10 and onwards (18,24,46). The large variability 
between the studies though, may be due to several factors, including the site of the disease, IMRT 
beam arrangement and daily set-up factors. Hunter et al (61) noted that there was individual 
patient variability in dose to the parotid glands, with some glands showing an increase in dose, and 
others a reduction in dose. However, in all glands where a reduction in dose was noted, the 
contralateral gland had an increased dose; suggesting that patient rotation at set-up may have 
influenced the outcome. They report an overall average increase in mean parotid dose of 0.92 Gy; 
but in those glands which had an increase in mean dose (i.e. excluding the glands with a dose 
reduction), this was in the magnitude of 2.2 Gy. Robar et al (50) demonstrated that there was an 
average increase in mean dose in only the left parotid gland, suggesting that disease location and 
IMRT beam arrangement may also have influenced the dose deposition in the parotid glands. 
Hansen et al (42) also demonstrated a discrepancy between dose of the right and left parotid 
glands.  
Castelli et al (38) report that there was an increase in parotid gland dose beyond acceptable dose 
constraints in 59 % of cases, leading to an increase in xerostomia risk by 8 % using NTCP modelling. 
When comparing the ipsilateral (or treated) versus the contralateral (or spared) parotid gland, the 
ipsilateral gland receives a significantly increased dose compared to the contralateral gland; 
Fiorentino et al and Bhide et al both report significant increases in parotid gland dose in the 
ipsilateral glands only (11,60); whereas Cheng et al (20) report the increase in dose to the 
ipsilateral and contralateral glands being 34 % and 10 % respectively. Loo et al (39) however 
report the opposite trend, with contralateral parotid glands receiving a greater increase in mean 
dose than the ipsilateral glands; however they state that the whole gland was not imaged in all 
cases, as dose was calculated on parotid glands identified on Cone Beam CT images.  
A small number of investigators have reported that the parotid gland dose does not significantly 
increase during radiation therapy (21,31); however in the study by Height et al (31) only 4 patients 
had lymph node disease in the neck and this may have affected their results. In the study reported 
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by Ho et al (21), most patients had either received neoadjuvant chemotherapy to reduce bulky 
disease in the neck or had undergone a neck dissection prior to radiation therapy. 
 
2.5.2 Spinal Cord and Brainstem 
 
Some investigators have studied the impact of anatomical changes during RT on the dose delivery 
to the spinal cord and brainstem. All studies have assessed the maximum dose (Dmax) to the spinal 
cord and many have also reported the highest dose to 1 cc (D1cc) of the spinal cord; although there 
is a variation in the timings of repeat imaging for dose calculations. Other measures, include highest 
dose to 2 cc (D2cc) in relation to the spinal cord and highest dose to 1 % of volume (D1%) in 
relation to the brainstem. In general, the spinal cord receives a higher Dmax than was originally 
planned; ranging from 1.2 to 2.5 Gy increase in dose (18,20,21,24,29,35,53). Ahn et al (18) report 
that 30 % of their patient cohort (7 of 23) exceeded spinal cord tolerance dose; whilst Cheng et al 
(20) report 11 % (2 of 19) of their patient cohort exceeded spinal cord tolerance dose at 30 and 50 
Gy. Whilst not finding an increase in spinal cord Dmax, Nishi et al (33) report an average increase of 
1.9 Gy in the D2cc of the spinal cord. Qi et al (26) report a Dmax increase of 3 Gy, but this was not a 
statistically significant value in their patient cohort. Increase in spinal cord dose can occur in the 
first half of treatment (24,35), with Huang et al (25) reporting statistically significant increases 
from fraction 5. 
Increase in brainstem delivered dose has been reported only in studies of patients with 
nasopharyngeal cancer; with an average increase in Dmax between 0.2 and 2.7 Gy (20,24,25,35,59). 
Cheng et al (20) report 11 % and 16 % of their patient cohort exceeded brainstem tolerance dose at 
30 and 50 Gy respectively. Zhang et al (59) report that whilst maximum spinal cord dose remained 
within the dose constraints, the brainstem maximum dose exceeded dose constraints in 20 % of 
patients. Similar to spinal cord, an increase in brainstem dose occurs in the first half of treatment 
from as early as fraction 15 (20,24,25,35). 
Spinal cord and brainstem dose delivery can be impacted by daily set-up variations; Han et al (49) 
demonstrated an increase in spinal cord Dmax of up to 0.5 Gy if daily set-up corrections were not 
undertaken. 
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2.5.3 Other OARs 
 
The difference between planned and delivered dose has been less well-studied in other OARs; 
therefore findings are more sparse and inconsistent. 
Castadot et al (58) report a 0.9 Gy increase in mean dose delivered to the submandibular glands. 
They also report that the doses to larynx and mandible were not elevated, but there was a small 
increase of 0.7 Gy in delivered mean dose to the oral cavity as a result of anatomical changes. An 
increase in oral cavity dose was reported by Beltran et al (53); by contrast Ho et al (21) report no 
significant changes in mean doses to the larynx and oral cavity. Cozzolino et al (46) report an 
increase in laryngeal dose, but the dose remained within the planning dose constraints. Some 
investigators report no significant changes in mandible dose  (40,42,53), though Cheng et al (20) 
report an increase in mean mandible dose. Cheng et al also report increase in Dmax dose to the 
optic nerve and ipsilateral eyeball in their cohort of patients being treated for nasopharyngeal 
cancer. Huang et al (25) in their cohort of nasopharyngeal carcinoma patients report inconsistent 
variable dose increase to the glottis, eyes and lens. They also report no significant differences 
between planned and delivered doses to the temporal lobes, optic nerves, optic chiasm, cochleae, 
mandible, oral cavity, supraglottis and subglottis. No conclusion can be made from these data as the 
measures are not comparable. 
 
2.6 Clinical Impact of Dosimetric Changes during Radiation 
Therapy 
 
Normal tissue complications from radiation therapy can have a significant effect on the Quality of 
Life of a patient (62). Dose volume effects have been described in the literature with respect to 
significant OARs for head and neck radiation therapy, i.e. the parotid and submandibular glands, 
spinal cord, brainstem and swallowing structures. For the salivary glands, increased dose to the 
parotid and submandibular glands leads to an increased incidence and severity of xerostomia; 
which can have a lasting impact on dental hygiene, risk of oral infections and difficulties with 
chewing and swallowing (56,63,64), as well as adversely affecting Quality of Life (65). Increased 
swallowing complications, including dysphagia, stricture and aspiration, and subsequent Quality of 
Life impact are observed with higher doses to the larynx and constrictor muscles (66–71). 
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Dose constraints have been developed, based on clinical studies looking at dose-volume effects, and 
published in the QUANTEC papers (56,68,72,73). These analyses are often based on retrospective 
data in heterogeneous patient populations, using different treatment techniques, margins and dose 
prescriptions and with differing end-points; therefore these are limitations to consider in the 
interpretation of these dose constraint measures (5,74). Additionally, dose-volume data are derived 
from dose-volume histograms of planned dose distributions and do not take into account the 
dosimetric impact of anatomical changes occurring during radiation treatment. Nevertheless, these 
studies are the best information we currently have; hence widely used to guide radiation treatment 
planning.  
More recently, some investigators have reported dose effects on radiation toxicity and Quality of 
Life based on delivered doses (rather than planned dose delivery), although the literature is limited. 
An increase in delivered dose to the parotid glands is associated with increased xerostomia risk, 
using Normal Tissue Control Probability (NTCP) modelling (32,38). Hunter et al (61), in comparing 
planned versus actually delivered parotid gland dose on salivary output, report that the delivered 
parotid gland dose did not correlate better with saliva production than the planned parotid gland 
dose. However, if the delivered dose was ≥ 0.1 Gy more than planned dose on day one of treatment, 
this correlated with a ≥4 Gy increase in delivered dose to the parotid glands than planned. Zhao et 
al (35) conducted a retrospective matched case-control study comparing outcomes in patients who 
had their IMRT plans adapted at fraction 15 to those who did not undergo plan adaptation. Patients 
whose plans were adapted received lower dose to their parotid glands and subsequently 
experienced lower xerostomia severity. In a prospective case-control study, 89 nasopharyngeal 
cancer patients who underwent plan adaptation at fraction 15 or 25, had improved global and 
symptom specific Quality of Life scores compared to the 43 patients who did not have plan 
adaptation, though dosimetric analysis was not performed in this study (75). 
 
2.7 The Benefit of Adaptive Radiation Therapy in Head and 
Neck Cancer Patients 
 
The previous sections have explored the morphological changes occurring in patients during 
radiation therapy; and the subsequent impact on the delivered dose to target volumes and organs 
at risk. This can have a clinical impact in terms of radiation toxicity and Quality of Life, as well as a 
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potential impact on tumour control probability.  Therefore patients may benefit from an ART 
approach; whereby a new treatment plan is created during the course of radiation therapy to 
account for the morphological changes which have occurred. This section reviews the literature on 
the impact of ART. 
 
2.7.1 Impact of ART on Tumour Dose and Clinical Outcome 
 
The data on the impact of ART on tumour dose and outcome are summarised in Table 2.1; the 
results showing variability in benefit. Improved tumour target volume coverage, in terms of dose 
and dose homogeneity, occurs with plan adaptation in some studies (18,35,41,52,58,76). Ahn et al 
(18) conducted a prospective study of 23 patients undergoing chemoradiotherapy for HNC. The 
radiotherapy prescription was 66 to 69.6 Gy in 33 fractions to the primary PTV, with lower doses to 
at risk and low risk nodal regions. The primary PTV was then boosted to 72 Gy; with a total number 
of 40 fractions. Re-imaging with planning CT scans was performed at fractions 11, 22 and 33. 
Tumour and OAR criteria were specified for triggering a plan adaptation; specifically PTV D95 less 
than 95 % of prescription dose, Dmax >45 Gy for the spinal cord, D50>26 Gy for the parotid glands, 
brainstem V54 >20 % and mandible V60 >10 %. Of the 15 patients (65 % of the cohort) who 
benefited from plan adaptation, 14 received a benefit in PTV coverage and dose homogeneity, 
though the extent of benefit has not been quantified in the paper. The benefit to organs at risk is 
described in the section 2.7.2. 
Castadot et al (58) compared the planned, delivered and adapted dose distributions at four time 
points in their cohort of 10 patients undertaking chemoradiotherapy to a dose of 69 Gy over 30 
fractions. Re-imaging was undertaken with contrast-enhanced CT scans and manual contouring of 
the regions of interest was performed. Though their patients did not receive the actual adapted 
plans, a small but significant improvement in coverage of the low dose PTV and CTV was reported; 
in contrast the adapted doses to the high dose PTV and CTV were actually lower than the delivered 
dose. The authors suggest that this may have been due to a volume reduction in the high dose CTV 
and PTV volumes.  Zhang et al (41) report, in their study of 13 patients with oropharyngeal cancer, 
that the high dose CTV coverage was improved with weekly plan adaptations. 
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Jensen et al (52) took a different approach, whereby dose calculation and plan adaptation was only 
undertaken if there was a ≥1 cm discrepancy in contours over a minimum of 3 CT slices, during 
weekly imaging in 72 patients. 15 patients (21 %) underwent plan adaptation; with a higher 
proportion of the plan adaptations occurring in patients with nasopharyngeal or hypopharyngeal 
tumours. Due to the study design, they only report on the dosimetric outcome of those patients who 
underwent plan adaptation, as dose calculations were not performed on all patients. In these 
patients, plan adaptation resulted in improved nodal volume coverage, especially in the lower neck. 
There are some investigators who have reported no benefit with plan adaptation in terms of 
tumour dose (23,24,27,40,59,77); though the organs at risk did benefit from the plan adaptations 
that were performed (section 2.7.2). One of these studies does not specify which tumour target 
volume was being investigated and two of these studies look at dose to the CTV +/- GTV (23,59). It 
would be expected that there is more acceptable dose coverage to the CTV than when examining 
dose to the PTV, as the CTVs should be situated well within the high dose area with a larger 
distance to regions of steep dose gradient. However, it should be noted that Schwartz et al did not 
add an expansion margin for PTV when undertaking adaptive planning (23).  By contrast, Wang et 
al (76) report an improvement in coverage of the CTV (high dose) and GTV with plan adaptation at 
fraction 25; with percentage coverage of the CTV increasing by 4.9 % to 91.6 % with replanning. 
There are only three studies reporting clinical outcomes as a result of ART in head and neck cancer 
patients. Two of these are prospective studies, and despite there being selection bias in both 
studies, the results are still worth noting. Yang et al (75) conducted a prospective study in 129 
patients with nasopharyngeal cancer. Their patients were offered a repeat CT scan at fraction 15 or 
25 (or both) and the treatment plans were adapted to the new anatomy. 89 patients underwent 
repeat imaging, and their outcome data are compared to the outcomes of the 43 patients who 
refused repeat imaging. Those patients whose plans were adapted had a small but significant 
improvement in two year local regional control compared to the patients who did not have plan 
adaptations; 97 vs. 92 %. There was no difference in two year overall survival rates between the 
groups. The dosimetric difference between the two groups was not reported. Similarly, Chen et al 
(78) conducted a prospective study of 317 patients with head and neck cancer, undergoing 
definitive or adjuvant radiation therapy. Patients received plan adaptations if requested by the 
treating physician; based on a clinical assessment of weight loss, tumour shrinkage, mask fitting or 
if the patient had a prolonged treatment break. The patients selected for ART had significantly 
different characteristics (indicating selection bias) in that they were more likely to be receiving 
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definitive (rather than adjuvant) treatment and therefore also more likely to be receiving 
concurrent chemotherapy (p= 0.01) . The patients selected for ART were also more likely to have 
higher tumour (T) and nodal (N) tumour classification; though this was non-significant. Of the 51 
(16 %) patients who underwent ART, there was superior two year local regional control than the 
unadapted patients; 88 % vs. 80 %; despite these patients tending to have more advanced disease. 
There were no differences in overall survival rates. 
In a retrospective case-controlled study, Zhao et al (35) investigated the effect of plan adaptations 
on 33 patients with nasopharyngeal carcinoma, who underwent repeat imaging at fraction 15 with 
plan adaptation. Their dosimetric and clinical outcomes were compared to a historical cohort of 66 
patients undergoing the same treatment without plan adaptation. In those patients with T3 or T4 
tumours, plan adaptation resulted in improved three year progression free survival rates of 73 % 
vs. 68 % for the unadapted cohort; with a median progression free survival benefit of two months 
(50 months vs. 48 months). From a dosimetric perspective, plan adaptation resulted in improved 
coverage of the CTV.
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Study N RT dose 
(Gy) 
Timing of 
imaging 
ART effect Adaptive plan 
trigger 
Patients 
treated 
with ART 
Ahn et al, 
2011 (18) 
23 72 F11,22,33  14/23 (61 %) benefit in PTV coverage 
and dose homogeneity 
 
If exceed dose 
constraints 
Y 
Capelle et al, 
2012 (27) 
20 66 F15  Decr D1 for high dose PTV 0.3 Gy 
 Decr D1 for low dose PTV 0.6 Gy 
 
All scans Y 
Castadot et al, 
2011 (58) 
 
10 69 14.2, 24.5, 35.0, 
44.9 Gy 
 Incr D95 for low dose PTV 0.4 Gy + CTV 
0.3 Gy 
 Decr in D95 for high dose PTV 4.6 Gy + 
CTV 3.1 Gy 
 
All scans N 
Chen et al, 
2014 (78) 
317 66 At clinician 
discretion  
 Incr 2yr LRC 88 % vs. 80 % 
 No effect on 2 yr OS 
 
At clinician 
discretion 
Y 
Hansen et al, 
2006 (42) 
13 70 If tumour 
shrinkage &/or 
weight loss 
 
 Incr D95 for high dose PTV 2.2 Gy + low 
dose PTV 3 Gy 
 
All scans Y 
Jensen et al, 
2012 (52) 
72 66 to 72 Weekly  15/72pts (21 %) underwent ART 
 More ART events in pts w NPC and HPX 
ca 
 Improved coverage of elective LN 
volumes 3.7 % and supraclavicular nodal 
area 8.3 % 
 
If contour 
deviation ≥1 cm 
on 3 CT slices 
Y 
Schwartz et al, 
2012, 2013 
(23,77) 
22 66 to 72 Weekly  All pts had 1 replan; 8/22pts (36 %) had 
2 
 No benefit to CTV coverage 
 
All scans + if 
significant 
discrepancy of 
contour overlays 
 
Y 
Wang et al, 
2010 (24) 
15 66 F18  No benefit to PTV coverage 
 
All scans N 
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Wang et al, 
2010 (76) 
28 70-76 F25  Incr % of prescription dose to high dose 
CTV by 4.9 % 
 Incr % of prescription dose to GTV by 7.8 
% 
 
All scans Y 
Wu et al, 2009 
(40) 
11 70 Weekly  “Minimal effect on target volume 
coverage” 
 
All scans N 
Yang et al, 
2013 (75) 
129 70 to 76 F15, 25 or both  Incr 2yr LRC 97 % vs. 92 % 
 No effect on 2 yr OS 
 
All scans Y 
Zhang et al, 
2012 (59) 
 
11 69.96 to 
73.92 
Weekly till 
week5 
 No benefit to GTV + CTV coverage Week 5 N 
Zhang et al, 
2016 (41) 
 
13 70 Weekly  Incr high dose CTV D98 All scans Y 
Zhao et al, 
2011 (35) 
33 70 F15 (mean)  Incr CTV  D95 
 Incr 3yr local PFS in T3/4 pts 73 % vs 68 
% (compared to matched case-control) 
 Incr median PFS from 48 to 50 months 
All scans Y 
 
Table 2.1. Studies reporting on effect of plan adaptation on target volume coverage and clinical tumour outcomes  
N- number of patients, RT- radiation therapy, Gy- Gray, ART- Adaptive Radiation Therapy, F- fraction, Incr- increase, Decr- decrease, Y- 
yes, N-no, PTV- Planning Target Volume, CTV- Clinical Target Volume, GTV- Gross Tumour Volume, NPC- nasopharyngeal carcinoma, HPX- 
hypopharyngeal carcinoma, LN- lymph node, LRC- local regional control, OS- overall survival, QoL- Quality of Life, D95- minimum dose to 
95 % of volume, D98- minimum dose to 98 % of volume, D1- maximum dose received by 1 % of the volume, PFS- progression free 
survival.  
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2.7.2 ART Impact on Organ At Risk Dose and Clinical Outcome 
 
The data on the impact of ART on OARs are summarised in Table 2.2; the majority of studies 
reporting the impact on parotid glands, with fewer reporting on spinal cord and brainstem dose. 
Almost universally, adaptive planning results in improved dose distribution to the parotid glands 
and spinal cord, compared to no adaptation.  
Ahn et al (18) report that 15 of 23 patients (65 %) benefited  from plan adaptation; seven of them 
had an improvement in spinal cord dose, five in parotid gland dose and 14 experienced tumour 
dose coverage improvement. Similarly, Wang et al (76), in a study of 28 patients undergoing 
treatment for nasopharyngeal carcinoma using the RTOG0225 protocol and imaged at fraction 25, 
reported that 14 of 28 (50 %) of plans were non-compliant for OAR dose constraints. 11 plans 
exceeded brainstem, six exceeded spinal cord and four exceeded parotid gland dose constraints. 
Adaptive planning subsequently reduced the dose to these OARs. Castelli et al (38) conducted a 
prospective investigation of weekly non-contrast CT imaging and looked at the potential effect of 
plan adaptations. 11 of 15 patients (73 %) would have benefited from ART in terms of parotid gland 
dose. In those patients whose parotid gland experienced overdosing, weekly replanning would have 
reduced the mean dose to a similar value (or less) than the pre-treatment planning level. A 5.1 Gy 
reduction in mean dose was observed in the overdosed parotid glands; whilst a smaller but still 
significant 1.4 Gy mean dose reduction was observed in the non-overdosed glands.  
Zhang et al (41), in a prospective study, quantified the impact of different ART strategies (in terms 
of frequency and timing) on parotid gland dose delivery. Increasing the frequency of plan 
adaptations resulted in progressive improvement in parotid gland dosimetry; weekly plan 
adaptation reduced the mean parotid gland dose by 3.3 Gy (with a maximum benefit of 10.8 Gy). 
However, a 3.1 Gy mean parotid gland dose reduction was achieved with three plan adaptations (at 
weeks 1, 2 and 5), leading the authors to recommend a frequency of three plan adaptations as a 
pragmatic approach with respect to dose benefit and resource allocation. Wu et al (40) performed a 
retrospective study, investigating the effect that the number of plan adaptations would have on 
parotid gland dose delivery. Whilst a single mid-treatment plan adaptation resulted in 3 % 
reduction in parotid mean dose, the magnitude of benefit increased with the number of plan 
adaptations; 5 % for two adaptations and 8 % for six weekly adaptations. 
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A benefit in terms of dose reduction to OARs is worthwhile achieving only if it translates into a 
clinical benefit. However, the literature available is sparse, with small patient numbers and each 
individual investigation having its limitations. Castelli et al (38) report that a reduction in mean 
parotid gland dose of 5.1 Gy would reduce xerostomia risk by 11 %, using NTCP modelling. Their 
investigation did not treat the patients with adapted plans and therefore they report only a 
theoretical outcome. Yang et al (75) report, in a non-randomised study of 129 patients, a Quality of 
Life improvement with the use of ART. This included both global and head and neck specific Quality 
of Life scores. The limitations of their study have been discussed in section 2.7.1 above. However, in 
their retrospective case-matched review of 33 patients, Zhao et al (35) note that whilst a reduction 
in parotid gland dose coverage was observed, this did not translate to significant improvements in 
early or late toxicity scores. However, this study also has methodological limitations; it is non-
randomised and evaluation is retrospective.  
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Study N RT dose 
(Gy) 
Timing of 
imaging 
ART effect Adaptive plan 
trigger 
Patients 
treated 
with ART 
Ahn et al, 
2011 (18) 
23 72 F11,22,33  5/23 (22 %) benefit in PG sparing 
 7/23 (30 %) benefit in SpC dose 
 
If exceed dose 
constraints 
Y 
Capelle et al, 
2012 (27) 
20 66 F15  Decr SpC Dmax 0.4 Gy 
 Decr PG Dmean 0.6 Gy (NS), V26 3.8 % 
(NS) 
 
All scans Y 
Castadot et al, 
2011 (58) 
10 69 14.2, 24.5, 35.0, 
44.9 Gy 
 Decr in D2 for SpC + Dmean for oral 
cavity 
 No significant benefit for PG, SMG, 
mandible + larynx 
 
All scans N 
Castelli et al, 
2015 (38) 
15 70 Weekly  Decr PG Dmean 5.1 Gy (overdosed PG), 
1.4 Gy (non-overdosed PG) 
 Decr xerostomia risk 11 % in overdosed 
PG  
 
All scans N 
Hansen et al, 
2006 (42) 
13 70 If tumour 
shrinkage &/or 
weight loss 
 Decr PG Dmean 2.9 Gy (R) 0.2 Gy (L) (NS) 
 Decr PG V26 10 % (R); incr 0.7 % (L) 
(NS) 
 Decr Dmax 4 Gy SpC + 2.6 Gy BS 
 Decr D1cc 3.1 Gy SpC + 2.3 Gy BS (NS) 
 Decr Dmax  mandible 1.4 Gy 
 
All scans Y 
Jensen et al, 
2012 (52) 
72 66 to 72 Weekly  15/72pts (21 %) underwent ART 
 More ART events in pts w NPC and HPX 
ca 
 Decr in PG Dmean 3.9 % ipsi, 11.5 % 
contra 
 
If contour 
deviation ≥1 cm 
on 3 CT slices 
Y 
Kuo et al, 
2006 (55) 
10 72 45 Gy  Decr PG Dmean 3 Gy (L) 3.2 Gy (R) 
 
All scans Y 
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Nishi et al, 
2012 (33) 
20 60 to 70 Week 3 or 4  Decr PG Dmean 10.3 Gy 
 Decr SpC D2 2.4 Gy (marginally 
significant) 
 
All scans Y 
Schwartz et al, 
2012, 2013 
(23,77) 
22 66 to 72 Weekly  All pts had 1 replan; 8/22pts (36 %) had 
2 
 1 replan- Decr PG Dmean 0.6 Gy contra, 
1.3 Gy ipsi 
 2 replan- Decr PG Dmean 0.8 Gy contra, 
4.1 Gy ipsi 
 
All scans + if 
significant 
discrepancy of 
contour overlays 
Y 
Wang et al, 
2010 (24) 
15 66 F18  Decr PG Dmean 1.3 Gy (R) 1.4 Gy (L)  
 Decr PG V26 5.4 % (R) 5.7 % (L) 
 Decr Dmax 3 Gy SpC + 1.9 Gy BS 
 Decr D1cc 2.6 Gy SpC + 1.4 Gy BS 
 
All scans N 
Wang et al, 
2010 (76) 
28 70-76 F25  Decr PG Dmean 3.2 Gy (R) (NS) 4.2 Gy (L)  
 Decr PG V30 11.5 % (R) 8.1 % (L)(NS) 
 Decr Dmax by 5 Gy SpC 
 Decr Dmax by 4 Gy BS (NS) 
 
All scans Y 
Wu et al, 2009 
(40) 
11 70 Weekly  1 replan- Decr PG Dmean 3 % 
 2 replans- Decr PG Dmean 5 % 
 6 replans- Decr PG Dmean 8 % 
 
All scans N 
Yang et al, 
2013 (75) 
 
129 70 to 76 F15, 25 or both  Improved global and H+N specific QoL 
 
All scans Y 
Zhang et al, 
2012 (59) 
11 69.96 to 
73.92 
Weekly till 
week5 
 Decr PG Dmean 3.8 Gy (R) 5.3 Gy (L)  
 NS decr SpC Dmax 3 Gy, D1 1.2 Gy 
 NS decr BS Dmax 5.9 Gy, D1 6.2 Gy 
 
Week 5 N 
Zhang et al, 
2016 (41) 
13 70 Weekly  Decr PG Dmean by a mean/maximum 
value of: 
All scans Y 
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 1 ART 2.2/10 Gy 
 2 ART 2.9/10.6 Gy 
 3 ART 3.1/11 Gy 
 4 ART 3.2/10.8 Gy 
 5 ART 3.3/10.8 Gy 
 6 ART 3.3/10.8 Gy 
 
Zhao et al, 
2011 (35) 
33 70 F15 (mean)  Decr PG Dmean  
 Decr Dmax SpC + BS 
 NS difference in early/late toxicity 
 
All scans Y 
 
Table 2.2. Studies reporting on effect of plan adaptation on OAR coverage and clinical outcomes  
N- number of patients, RT- radiation therapy, Gy- Gray, ART- Adaptive Radiation Therapy, F- fraction, PG- parotid gland, SpC- spinal cord, 
Incr- increase, Decr- decrease, D2- minimum dose to 2 % of volume, Dmean- mean dose, SMG- submandibular gland, NPC- nasopharyngeal 
carcinoma, HPX- hypopharyngeal carcinoma, ipsi- ipsilateral, contra- contralateral, R- right, L- left, BS- brainstem, V26- volume receiving 
26 Gy, V30- volume receiving 30 Gy, Dmax- maximum dose, D1cc- dose to 1 cc of volume, NS- statistically non-significant, H+N- head and 
neck, QoL- Quality of Life, D95- minimum dose to 95 % of volume, PFS- progression free survival. 
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2.8 Implementation of ART for Head and Neck Cancer Patients  
 
2.8.1 Clinical Resource Impact  
 
The clinical implementation of an ART protocol for HNC patients, using multiple repeat CT scans, is 
a resource intensive process. On average, the time taken to manually contour the required 
anatomical structures, in the head and neck region, is over two hours (79–81). Additional time and 
labour is required for dosimetry calculation, with subsequent plan generation and Quality 
Assurance procedures if a plan adaptation is implemented.  
Furthermore, not all patients may benefit from treatment plan adaptation, with the proportion of 
patients who experienced a dosimetric benefit varying widely (18,23,38,52,76). Ahn et al (18), who 
imaged at three time points during the treatment course, demonstrated that 65 % of their patients 
(15 of 23) required replanning. 14 of the 15 patients (61 %) with inadequate plans had insufficient 
PTV coverage, 7 (30 %) and 5 (22 %) exceeded spinal cord and parotid gland dose constraints 
respectively. Wang et al (76), using a single re-imaging, reported that 50 % of unadapted plans 
were noncompliant for OAR dose criteria. Jensen et al (52) report that 21 % of their cohort 
underwent plan adaptation, however this decision was based on an assessment of differences in 
contour overlay, rather than a dosimetric evaluation.  
In the study by Schwartz et al (23), all 22 patients appeared to require at least one replan due to 
“CTV and normal tissues changes”. Since underdosing of the CTV was not observed, they suggest 
that plan adaptation was required due to excessive OAR dose. This is a higher rate of plan 
adaptations required than other reports; it may be due to the frequency of CT scanning and 
dosimetric analysis (weekly) being more frequent in this patient cohort.   Castelli et al (38) also 
conducted weekly CT imaging, specifically investigating the parotid gland dose delivery. They 
report that 11 of 15 patients (73 %) would have benefited from ART in terms of parotid gland dose. 
Therefore, in terms of the most appropriate allocation of limited resources, the ability to identify 
those patients who would most benefit from the ART process is highly relevant. Equally important 
is the determination of the best timing for ART. 
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2.8.2 Factors Which Correlate with Inadequate Dose Delivery  
 
In order to best allocate limited resources, the recognition of patients who would gain most benefit 
for ART is extremely beneficial. In an ideal setting, easily measurable surrogate measures of 
inadequate plan dosimetry would allow for a patient’s treatment plan to be efficiently assessed and 
reoptimised.  
Investigators have reported correlations of plan dosimetry with factors such as weight loss, 
changes in tumour volume and parotid gland volume, initial volume of parotid glands and medial 
parotid gland displacement; these are summarised in Tables 2.3 to 2.5. The correlations with 
parotid gland (Table 2.3) and spinal cord dose (Table 2.4) have been most frequently reported, 
however, some data regarding submandibular gland, tumour volume, brainstem and mandible dose 
are also available (Table 2.5). It is impossible to draw strong conclusions from these reports, as the 
investigations often involve small patient populations, with the identification of measures of plan 
inadequacy not being the primary objective of the study. Although statistically significant findings 
are reported, correlations are often weak and no single factor stands out from the numerous 
correlations reported. A factor found to be correlated with inadequate dose delivery in one report, 
may not be significantly correlated in another report.  Additionally, different statistical measures 
have been used to describe associations, and the variability of tests makes it difficult to directly 
compare different papers. 
Despite these limitations, some investigators have attempted to generate models to predict 
whether a patient requires plan adaptation. Castelli et al (82) generated a nomogram, based on the 
data of 20 patients, to predict parotid gland dose. They report that their nomogram has a sensitivity 
of 80 %, specificity 60 %, positive predictive value 86 % and negative predictive value of 50 %. In 
patients who were identified with overdose to the parotid glands, using this nomogram, plan 
adaptation resulted in a reduction in mean parotid gland dose of 3.9 Gy and a resultant reduction of 
xerostomia risk of 8 %.  
Brown et al (83) have also proposed a model to predict the need for plan adaptation, based on the 
tumour site, nodal stage at diagnosis, patient weight and initial nodal size. Patients are classified 
into low, intermediate and high risk groups, with a >80 % probability of requiring plan adaptation 
in high risk patients and 60-80 % probability in intermediate risk patients.  This model was 
developed based on a study of 110 patients, who underwent CT imaging at fraction 15. Based on 
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target volume and OAR coverage, a decision to undertake plan adaptation was made. Of the 100 
patients, only 5 required plan adaptation at fraction 15, which is a small proportion compared to 
the frequency in other studies mentioned in section 2.8.1.  
Brouwer et al (84) took a different approach to the selection of patients for ART, based on the risk 
of receiving >3 Gy excess in parotid gland dose. Whilst many factors were associated with change in 
the mean dose to parotid glands on univariate analysis, only the planned mean parotid gland dose 
was found to be significant on multivariate analysis. By selecting those patients with a mean parotid 
gland dose of 22.2 Gy or above at planning, 76 % of parotid glands (ipsilateral or contralateral) 
would be selected for plan adaptation. However, their model had a low positive predictive value of 
19 %; i.e. only 19 % of the glands selected actually needed ART due to >3 Gy excess dose delivery. 
The negative predictive value of their model was 81 %, suggesting that the model is best used to 
identify those patients who would derive less benefit from plan adaptation. Whilst these models are 
potentially useful tools, validation in larger patient cohorts should be performed. 
The interfraction positional variation of patient anatomy also has a significant effect on dose 
delivery (18,49,51,61). Ahn et al (18) report significant correlations between positional variation 
and dose delivery to parotid glands, target volumes, spinal cord and mandible. Hunter et al (61) 
found that if the delivered PG dose on day 1 was ≥0.1 Gy more than planned, this correlated with ≥4 
Gy increase in delivered dose to the parotid glands at the end of radiation therapy. However, 
rotational set up deviations, which could not be corrected for, also contributed to alterations in 
dose delivery. In contrast, Capelle et al (27) report that there was no correlation found between 
positioning variations and dose parameters. The movement of interstitial fluid could also cause 
tissue deformation, with subsequent impact on dose (85). 
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Study N Parotid gland endpoint Correlation parameter Correlation/ 
Association 
P value 
Ahn et al, 
2011 (18) 
23 D50 incr 
 
 
 
 
 
Need for replan due to D50 
overdose 
Neck diameter decr at 
mandibular joint 
Neck diameter decr at 
C1-5 level 
PG vol decr 
Weight loss 
Isocentre displacement 
Positional variation 
(mandible level) 
Neck diameter C2-3 level 
R 0.22-0.39 
 
R 0.15-0.28 
 
R 0.22 
R 0.30-0.35 
nr 
nr 
 
nr 
ss but nr 
 
 
 
 
 
0.002 
0.001-0.006 
 
0.07-0.08 
(ns) 
 
Brouwer et al, 
2016 (84) 
113 Dmean change Univariate analysis 
BMI 
Weight   
T stage 
N stage 
Planned PG Dmean 
Initial GTV volume 
Tumour location, 
Overlap of PG with PTV70 
Age, surgery, initial PG 
vol 
 
Multivariate analysis 
Planned PG Dmean 
 
R contra/ipsi 
-0.32/-0.38 
-0.24/-0.12 
0.34/0.28 
0.41/0.40 
0.76/0.62 
0.53/0.45 
0.41/0.31 
0.23/0.20 
Nil found 
 
 
 
R2 0.59/0.39 
 
contra/ipsi 
0.002/<0.001 
0.01/ns 
<0.003 
<0.0001 
<0.0001 
<0.0001 
<0.001 
0.02/0.03 
 
 
 
 
<0.001 
Capelle et al, 
2012 (27) 
20 Dmean Neck thickness change at 
mid-PTV level 
GTV volume, weight 
change, neck thickness at 
C1 vertebra and thyroid 
notch, T stage, N stage 
 
R 0.64 
 
Nil found 
<0.001 
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Castadot et al, 
2011 (58) 
10 Improvement in Dmean ipsi 
PG with ART 
∆ Dmean planned + 
delivered (contra PG)  
Change in PG Dmean 
Rate of GTV vol loss 
 
Rate of contra PG vol loss 
 
Initial tumour vol, GTV 
vol loss, inter-PG 
distance 
 
R2 0.65 
 
R2 0.62 
 
Nil found 
p= 0.005 
 
p=0.006 
 
Castelli et al, 
2015 (38) 
15 PG overdose + ART benefit 
 
Dmean 
CTV70 vol loss  
Neck thickness reduction 
PG vol loss 
 
nr 
nr 
Nil found 
p<0.01 
p<0.01 
 
Castelli et al, 
2016 (82) 
20 PG overdose CTV70 dose at planning 
∆CTV dose at week1 
Dmean PG at week1 
∆PG Dmean at week1 
PG Dmean week1/PG 
Dmean week0 
 
R2 0.32 
R2 -0.46 
R2 0.5 
R2 0.72 
R2 0.7 
0.038 
0.004 
<0.01 
<0.001 
<0.01 
Han et al, 
2008 (49) 
 
5 Delivered Dmean PG vol R -0.95 <0.01 
Hunter et al, 
2013 (61) 
18 ∆ Dmean planned + 
delivered 
∆ Dmean planned + 
delivered on Day1 
Weight change, initial PG 
vol, PG vol loss 
 
R 0.92 
 
Nil found 
<0.001 
Lee et al, 2008 
(85) 
10 ∆ Dmean planned + 
delivered 
PG COM change 
% weight change 
 
R2 0.88 
R2 0.58 
nr 
nr 
Marzi et al, 
2012 (32) 
15 ∆ Dmean planned + 
delivered 
∆ GTV vol 
Initial PG vol, PG vol 
change, planned PG 
Dmean, initial GTV vol, 
GTV vol change, weight 
change 
R 0.604 
Nil found 
0.017 
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Qi et al, 2015 
(26) 
11 Dmean deviation from plan 
 
 
COM displacement 
 
Weight loss 
 
R2 0.55 (R), 
0.39 (L) 
R2 <0.4 
nr 
Vasquez 
Osorio et al, 
2008 (34) 
 
10 Planned Dmean PG vol loss R 0.68 <0.001 
Wang et al, 
2010 (24) 
15 Change in Dmean Weight loss R 0.81 (L) 
R 0.89 (R) 
<0.001 
Wang et al, 
2009 (45) 
82 Dmean PG vol loss at end of RT R 0.404 <0.001 
Zhang et al, 
2012 (59) 
11 Change in Dmean Weight loss Nil found  
 
Table 2.3. Studies reporting correlations with parotid gland dosimetry. R is the correlation coefficient and R2 is the squared correlation 
coefficient. 
N- number of patients, PG- parotid gland, incr- increase, decr- decrease, vol- volume, nr- not reported, ss- statistically significant, ns- 
statistically non-significant, D50- dose to 50 % of volume, Dmean- mean dose, ∆- difference of the parameter, ipsi- ipsilateral, contra- 
contralateral, R- right, L- left, COM- centre of mass, BMI- body mass index, CTV70- Clinical Target Volume prescribed 70 Gy, PTV70- 
Planning Target Volume prescribed 70 Gy, T- tumour, N-nodal. 
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Study N Spinal cord or 
Brainstem endpoint 
Correlation parameter Correlation/ 
Association 
P value 
Ahn et al, 
2011 (18) 
23 Dmax SpC incr 
 
 
 
 
 
Need for replan due to 
SpC Dmax overdose 
Neck diameter decr at 
mandibular joint 
Neck diameter decr at 
C4-6 vertebral level 
Neck diameter decr at 
mid-tumour level 
Positional variations at 
base of skull, mandible, 
various levels of cervical 
spine, lordosis 
 
R 0.30 
 
R 0.17-0.27 
 
R 0.18 
 
nr 
ss but nr 
 
 
 
 
 
significant p 
values 
Capelle et al, 
2012 (27) 
20 Dmax SpC Neck thickness change at 
mid-PTV level 
Neck thickness change at 
thyroid notch level 
GTV volume, weight 
change, neck thickness at 
C1 vertebra, T stage, N 
stage 
 
R 0.56 
 
R 0.73 
 
Nil found 
0.01 
 
<0.0001 
Castadot et al, 
2011 (58) 
10 Difference between 
planned + delivered SpC 
D2  
Difference between 
delivered + ART SpC D2 
  
Rate of GTV vol loss 
 
 
Rate of GTV vol loss 
 
R2 0.79 
 
 
R2 0.75 
p= 0.0006 
 
 
p=0.001 
 
Nishi et al, 
2012 (33) 
 
20 D2 SpC incr GTVp vol loss R 0.91 nr 
Qi et al, 2015 
(26) 
11 Dmax SpC 
 
 
Weight loss 
 
Nil found  
Wang et al, 
2010 (24) 
15 Change in Dmax SpC 
Change in Dmax BS 
Weight loss 
Weight loss 
R 0.65 
Nil found 
<0.05 
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Zhang et al, 
2012 (59) 
11 D1 SpC, BS Weight loss Nil found  
 
Table 2.4. Studies reporting correlations with spinal cord and brainstem dosimetry. R is the correlation coefficient and R2 is the squared 
correlation coefficient. 
N- number of patients, SpC- spinal cord, BS- brainstem, incr- increase, decr- decrease, vol- volume, D1- dose to 1 % of volume, D2- dose to 
2 % of volume, Dmax- maximum dose, nr- not reported, ss- statistically significant, T- tumour, N- nodal. 
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Study N ROI endpoint Correlation parameter Correlation/ 
Association 
P value 
Target 
Volumes 
     
Ahn et al, 
2011 (18) 
23 PTV nodal D95 incr 
 
 
PTV tumour D95 incr 
 
 
 
PTV underdose 
 
 
 
PTV nodal underdose 
Neck diameter decr at 
C1-5 vertebral level 
PTV nodal vol decr 
Neck diameter decr at 
C1-3 level 
PTV tumour + nodal vol 
decr 
Isocentre displacement 
Positional variation at 
base of skull 
Weight loss 
Positional variations at 
base of skull, mandible, 
various levels of cervical 
spine 
 
0.19-0.25 
 
0.27 
0.23-0.24 
 
0.30-0.31 
 
nr 
 
 
 
nr 
ss but nr 
 
 
 
 
 
 
0.015 
0.063 (ns) 
 
0.099 (ns) 
significant p 
values 
Capelle et al, 
2012 (27) 
20 PTV low dose D1 
 
 
 
 
 
PTV high dose D1 
 
Weight change 
Neck thickness change at 
thyroid notch level 
GTV volume, neck 
thickness at C1 vertebra 
and mid-PTV, T stage, N 
stage 
Weight change, GTV 
volume, neck thickness 
at C1 vertebra, mid-PTV 
and thyroid notch, T 
stage, N stage 
 
R 0.59 
R 0.51 
 
Nil found 
 
 
Nil found 
0.01 
0.02 
 
 
Qi et al, 2015 
(26) 
11 Mean dose PTV 
 
 
Weight loss 
 
Nil found  
39 
 
Wang et al, 
2010 (24) 
15 TV dosimetric endpoints Weight loss 
 
Nil found  
Other OARs      
Ahn et al, 
2011 (18) 
23 Mandible V60 incr 
Mandible overdose 
 
GTV volume decr 
Isocentre displacement 
Positional variation at 
Base of Skull, mandible 
cochlea level 
 
0.26 
nr 
nr 
ss but nr 
0.001-0.002 
significant p 
values 
Vasquez 
Osorio et al, 
2008 (34) 
 
10 Planned Dmean SMG SMG vol loss Nil found  
Wang et al, 
2009 (45) 
82 Dmean SMG Vol loss at end of RT R 0.389 <0.001 
 
Table 2.5. Studies reporting correlations with dosimetry of other structures. R is the correlation coefficient and R2 is the squared 
correlation coefficient. 
N- number of patients, ROI- Region of Interest, incr- increase, decr- decrease, D1- maximum dose to 1 % of volume, D95- dose to 95 % of 
the volume, Dmean- mean dose, V60- volume receiving 60 Gy, TV- target volume, SMG- submandibular gland, T- tumour, N- nodal, vol- 
volume, nr- not reported, ss- statistically significant, ns- statistically non-significant. 
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2.8.3 Recommendations for ART Implementation 
 
The previous sections of this chapter have built an argument for the routine use of ART in HNC 
patients. However, there are numerous points to consider in the practical implementation of an 
ART protocol; including: 
i. Resource availability 
ii. Identifying patients who would most benefit from ART 
iii. Identifying the best timing for ART 
 
The impact on clinical resources has been discussed in section 2.8.1. Section 2.8.2 has explored how 
patients may be identified for plan adaptation. Section 2.5 has highlighted how anatomical changes, 
resulting in significant dosimetric alteration, have been identified early in the 35 fraction radiation 
therapy course. Some investigators have made recommendations for implementing an ART 
protocol, in terms of timing or selection criteria. These recommendations tend to mirror the 
specific protocols employed by the investigators and are summarised in Table 2.6. However, it is 
generally accepted that imaging and replanning early in the treatment course is beneficial. 
Recommendations on the selection criteria for patients who may benefit is more variable.  
Ahn et al (18) describe their approach to replanning their patients following a mid-course repeat 
CT scan. An assessment of target volume and OAR dose coverage is made, but they also take into 
account positional variations (based on daily CBCT imaging) as these have also been shown to 
significantly impact dose delivery. Brouwer et al (48) conducted a review of the anatomic changes 
and subsequent dosimetric consequences on OARs during HNC radiation therapy, to investigate 
whether any criteria to select patients for ART may be identified. They conclude that, since 
anatomical changes are more pronounced in the first half of treatment, the optimal timing for ART 
should be within this time period. Potential criteria to select patients for ART, which they 
recommend for further investigation in larger prospective trials, were tumour location 
(nasopharyngeal carcinoma), age, Body Mass Index (BMI), planned parotid gland dose and initial 
parotid gland volume. Brouwer et al (84), in a subsequent publication, propose a model for 
selecting patients for ART, based on the planned mean parotid gland dose at planning, as discussed 
in section 2.8.2 
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Study Selection criteria Timing 
Ahn et al, 
2011 (18) 
Based on dose to TV + OAR and positional 
variability 
 
Mid-course imaging 
Brouwer et al, 
2015 (48) 
Potential selection criteria for future 
investigation 
 
First half of treatment 
Brouwer et al, 
2016 (84) 
 
PG Dmean >22.2 Gy at planning  
Brown et al, 
2015 (83) 
High risk >80 % probability of replan 
Intermediate risk 60-80 % probability of replan 
Risk based on tumour location, nodal stage, 
initial nodal size, initial weight 
 
 
Castelli et al, 
2016 (82) 
Nomogram based on initial CTV dose, change in 
PG Dmean and change in CTV dose at week 1 
 
 
Cheng et al, 
2012 (20) 
 
 At 30 Gy 
Fiorentino et 
al, 2012 (86) 
 
 Week 3 
Huang et al, 
2015 (25) 
 
 Fractions 5, 15 
Zhang et al, 
2016 (41) 
 
 3x during RT at week 1,2,5 
 
Table 2.6. Studies reporting recommendations, in terms of selection criteria or optimal timing, for 
implementing an ART protocol.  
PG- parotid gland, Dmean- mean dose, CTV- Clinical Target Volume, RT- radiation therapy. 
 
2.9 A Tool for Assessment of Patient Nutritional Status  
 
This investigation will incorporate a nutritional tool; in the analysis of correlations between clinical 
measures and inadequate IMRT plan dosimetry. The nutritional tool selected is the Patient 
Generated Subjective Global Assessment (PG-SGA), which has been validated specifically in the 
oncology population (16,17,87). It involves the assessment of patient weight, nutritional intake, 
symptoms, patient functioning, metabolic stress and physical examination (Appendix 1). The 
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dietician performing the assessment is then able to provide a global assessment of the nutritional 
status (categories A, B, C), as well as a numerical score, which increases with worsening nutritional 
status. 
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Chapter 3 
 
Methods  
 
3.1 Study Design 
 
The study design is a prospective single arm feasibility study. The study protocol attained local 
Ethics Board approval. 
 
3.2 Study Population 
 
3.2.1 Patient Selection 
 
Eligible patients were identified upon attendance at radiation oncology clinic consultation. Ten 
participants were enrolled onto the study. Participants received information about the study 
verbally, were provided with a written Patient Information Sheet and had the opportunity to ask 
questions. All participants provided written informed consent and were aware that they could 
withdraw their consent at any stage. 
 
3.2.2 Eligibility Criteria 
 
The following eligibility criteria were applied during patient selection.  
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i. Histologically or cytologically confirmed in situ primary mucosal head and neck squamous 
cell carcinoma (HNSCC). 
ii. Treatment with primary radiotherapy with or without concurrent systemic therapy, with 
curative intent, to a dose of 70 Gy.  
iii. Measurable disease on CT scan. 
iv. ECOG performance status 0 to 2 (Appendix 2). 
v. Age ≥18 years.   
vi. Able to comply with all treatment and assessments. 
vii. Ability to understand and willing to sign a written informed consent document. 
 
3.2.3 Ineligibility Criteria 
 
The presence of the following criteria resulted in ineligibility for study participation.  
i. Prior radiotherapy to the head and neck region.  
ii. Prior surgery to the head and neck region, apart from excision of basal cell carcinoma or 
non-invasive squamous cell carcinoma of the skin.  
iii. Pregnant or lactating patients. 
 
3.3 Pretreatment Evaluation 
 
The following pretreatment evaluation was undertaken prior to study enrolment, and is 
summarised in Table 3.1. 
i. Patient history for confirmation of eligibility and ineligibility criteria. 
ii. Physical examination of primary tumour and nodal regions, including flexible 
nasoendoscopy. 
iii. Assessment of weight, ECOG performance status and nutritional score (PG-SGA).  
iv. Review of patient imaging; specifically the diagnostic CT scan, 18-Fluorodeoxyglucose 
Positron Emission Tomography (FDG-PET) scan and Magnetic Resonance Imaging (MRI) 
scan (if performed) to confirm the tumour site, laterality and tumour stage.  
v. Review and confirmation of patient histopathology. 
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Required 
Investigations Prestudy 
RT 
planning  
Fraction
5 
Fraction 
10 
Fraction 
15 
Fraction 
20 
Fraction 
25 
Fraction 
30 
Fraction 
35 
Clinical review          
Medical History ✔         
Histopathology report ✔         
Physical examination ✔         
ECOG Performance 
Status 
✔         
Weight ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
PG-SGA score ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
Imaging          
Diagnostic CT scan ✔         
PET scan ✔         
MRI scan optional         
Conventional planning 
CT scan  
✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ 
 
Table 3.1. Schedule of clinical patient review and imaging 
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3.4 Radiation Treatment Planning and Plan Assessment 
 
3.4.1 Radiation Treatment Schedule 
 
Patients underwent IMRT five days a week for a total of thirty five fractions. At every fifth fraction, 
commencing from fraction five and ending at fraction 35, a non-contrast conventional planning CT 
scan was acquired (Table 3.1). In the case of four patients, an additional conventional planning CT 
scan was acquired at fraction one, due to a protocol amendment. This was to investigate the 
morphological changes which may have occurred between radiation treatment planning and the 
start of treatment. 
A flowchart summarising patient imaging and plan assessment is presented in Figure 3.1. 
 
3.4.2 Planning CT Procedure 
 
The patient was immobilised with a thermoplastic head and shoulder mask in the supine position, 
to ensure adequate immobilisation during therapy and treatment reproducibility. A planning CT 
scan using Siemens SOMATOM Sensation 16-slice scanner (SIEMENS, Erlangen, Germany) was 
acquired with 2 mm axial slices and with the use of i.v. contrast. The CT scan extended from above 
the vertex of the skull superiorly to below the suprasternal notch inferiorly. The isocentre was 
placed at the inferior-anterior edge of the C4 vertebral body on mid-line.  
 
3.4.3 Target Volume Definitions 
 
All target volume and normal structure delineation was undertaken using the Pinnacle3 Treatment 
Planning System Versions 8.0m and 9.0 (Philips Medical Systems, Fitchburg, Wisconsin, USA) by the 
chief investigator and checked by a second radiation oncologist. Volume of interest contours were 
manually delineated using international consensus guidelines (88) and International Commission 
on Radiation Units and Measurements (ICRU) report 62 definitions (89).  
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Figure 3.1. Flowchart summarising patient imaging and plan assessment protocol. † Reimaging 
commenced at fraction 5 for all patients except patients 6 to 9, who underwent an additional CT 
scan at fraction 1 due to protocol amendment.  
Assessment of patient eligibility 
Pre-treatment patient procedures 
 Planning CT scan with i.v. contrast 
 Dietician assessment 
 
Manual delineation of contours 
At every 5th fraction (†) 
 Non-contrast planning CT scan 
 Dietician assessment 
Rigid registration with CT scan of 
current radiation treatment plan 
  
Manual delineation of contours 
  
Treatment plan dose calculation on 
newly acquired CT dataset 
  
Radiation Treatment Planning & 
Quality Assurance (QA) process 
 
Is treatment plan on current CT dataset 
acceptable? 
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Gross Tumour Volume was defined as visible tumour (labelled GTVp) and enlarged or suspicious 
lymph nodes (labelled GTVn), identified clinically and radiographically with CT, FDG-PET and MRI 
imaging. The Clinical Target Volume of the primary (CTVp) was defined by an expansion from the 
GTVp, to anatomical boundaries of subclinical risk. The CTV of the involved lymph nodes (CTVn) 
was a 3mm expansion of the GTVn into normal fat, with subsequent modification at anatomical 
boundaries, e.g. skin, muscle and air cavity. The CTV of uninvolved nodal regions (CTVn0) was 
delineated in the bilateral neck according to anatomical boundaries (e.g. air cavities, bones, fascial 
planes) and excluded the CTVp and CTVn volumes. Intraobserver variability, when creating CTVs, 
was minimized by recording the anatomical boundaries used when creating the target volumes, 
facilitating their reproduction in following weeks. The Planning Target Volume was obtained by a 
3mm expansion of the CTV, as per the institution IGRT protocol. Two PTVs were defined; PTV60 
(low dose PTV), which was an expansion of the CTVp + CTVn + CTVn0; and PTV70 (high dose PTV), 
which was an expansion of the CTVp + CTVn. Figures 3.2, 3.3 and 3.4 demonstrate the delineation of 
tumour volumes in one representative patient. 
Organ at Risk volumes were identified and contoured, including parotid and submandibular glands, 
spinal canal, mandible and mucosa. The spinal canal and mandible were auto-delineated using CT 
density threshold values. The mucosa was defined as a 2 mm annulus around the aerodigestive air 
column. Some normal tissues (such as the lens, optic nerves, optic chiasm) were included when 
considered at risk of exposure. Fat volumes were also auto-delineated using CT density thresholds. 
The fat volumes were delineated for a maximum of nine slices around the isocentre slice. 
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Figure 3.2. GTV and CTV delineation in a representative patient. Description of tumour volumes in 
section 3.4.3.  Red- GTVp, orange- CTVp, green- GTVn, light blue- CTVn, yellow- CTVn0 
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Figure 3.3. Tumour volume delineation in a representative patient, demonstrating construction of 
the PTV60. Description of tumour volumes in section 3.4.3.  Red- GTVp, orange- CTVp, green- GTVn, 
light blue- CTVn, yellow- CTVn0, blue- PTV60. 
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Figure 3.4. Tumour volume delineation in a representative patient, demonstrating construction of 
the PTV70. Description of tumour volumes in section 3.4.3.  Red- GTVp, orange- CTVp, green- GTVn, 
light blue- CTVn, purple- PTV70. 
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3.4.4 Dose calculation 
 
Dose calculation was performed using a collapsed cone convolution algorithm (90,91). This 
calculation is based on a previously developed convolution method (92). The dose calculation grid 
used was 2 mm x 2 mm x 2 mm. 
 
3.4.5 Treatment Prescription 
 
A total of 70 Gy (2 Gy/fraction) was prescribed to the PTV70; and 60 Gy (1.7 Gy/fraction) to the 
PTV60 using seven-field inverse-planned IMRT (93) with simultaneous integrated boost technique 
over 35 fractions. Treatment was delivered on Varian 21EX and 21iX linear accelerators, using step 
and shoot delivery. 6 MV photon beams were selected. Treatment commenced within a median of 
15 days (range 13-27) after planning CT. Daily IGRT using bone matched electronic portal imaging 
(EPI) correction was performed as per departmental protocol at the time. 
 
3.4.6 Weekly Imaging and IMRT Plan Assessment 
 
All patients underwent a non-contrast planning CT scan every fifth fraction after commencement of 
radiation therapy. Four patients also had an additional planning CT scan on day one of radiation 
therapy, due to a protocol adjustment. At each CT scan, the fit of the immobilisation mask was 
assessed by clinical inspection and additional bolus inserted or a new mask made if required. The 
newly acquired CT dataset was aligned to the original CT scan using rigid registration. Deformable 
Image Registration (DIR) software was not utilised in this investigation (as the technology was not 
available in the department at the time of data collection), and all contour adjustment was done 
manually.  
For each CT scan, the tumour volumes (i.e. GTVs, CTVs and PTVs), parotid glands and spinal canal 
were delineated by the chief investigator. The GTV was defined as the visible tumour (GTVp) and 
enlarged lymph nodes (GTVn) as seen on the newly acquired CT scan. The CTVp was delineated 
using the same principles as for the original planning CT scan; i.e. an expansion of the GTVp to the 
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same anatomical boundaries which had been defined in the planning CT scan. This was in order to 
reduce the risk of undertreating microscopic disease, which had been included in the original CTVp. 
The CTVn remained a 3 mm expansion of the GTVn, with modification at anatomical boundaries, e.g. 
skin, air cavity. The CTVn0 was generated according to the same anatomical boundaries defined for 
the planning CT scan. The PTVs were a strictly geometric construct; i.e. a 3 mm expansion of the 
relevant CTVs, as per the institutional IGRT protocol.  
The original treatment plan was recalculated on the new CT dataset and plan acceptability was 
assessed via pre-determined DVH parameters for PTV coverage and dose to spinal canal. An 
unacceptable plan was defined as V95 <95 % for the PTV70 or PTV 60; or a spinal cord Dmax ≥ 45 
Gy. The parotid gland dose was noted, but did not affect decision making. Unacceptable plans were 
re-optimised and this adapted plan used for subsequent treatment and for subsequent weekly 
comparison.  
The volume of the contoured structures (GTVs, CTVs, PTVs, parotid and submandibular glands) on 
the weekly CT imaging was recorded. The volume of subcutaneous fat was recorded, across a 
maximum of nine slices with the isocentre slice at the centre. Image registration was used to collate 
all of the parotid gland contours onto a single scan. Parotid gland movement was calculated by 
measuring the shift of the centre of mass (COM) coordinates relative to the original planning CT 
scan. It was acknowledged that any uncertainty in image registration would impact on the results of 
the contour comparison as image registration was used to collate all of the contours onto a single 
scan, however this method has been used in other investigations (94). The lateral border position of 
the parotid glands was calculated as half the width of the gland in the lateral direction from the 
COM point. Some submandibular glands were delineated retrospectively and therefore all contours 
were not collated onto a single scan. The submandibular gland movement was calculated by 
measuring the shift of the COM coordinates relative to the isocentre coordinates. This method is not 
as robust as the method used to calculate parotid gland shift.  
 
3.4.7 Weekly Patient Assessment 
 
Patients underwent assessment on the day of their initial planning CT scan and each time they 
underwent a repeat planning CT scan (Table 3.1). Weight was measured without shoes, with a 
similar amount of clothing and before chemotherapy if possible. A Patient Generated Subjective 
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Global Assessment (PG-SGA) was performed by a registered dietician (Appendix 1), in order to 
document the patient nutritional status.  
 
3.4.8 Statistical Analysis 
 
Graphpad Prism 6 for Windows (Version 6.05, La Jolla, CA, USA) and IBM SPSS software version 20 
(SPSS, Chicago, IL, USA) were used for statistical analysis. Sample t-tests were used to assess 
volumetric and geometric changes in target volumes and OARs, as well as dosimetric changes in the 
unadapted IMRT plans. Comparisons between the original and adaptive plans were performed 
using two-sided paired t-tests.  A probability value < 0.05 was considered significant. Correlation 
between patient nutritional score and weight versus PTV70 coverage over the treatment was 
investigated using Pearson’s correlation, since the Shapiro-Wilk test demonstrated that the data 
exhibited a normal distribution.  
 
3.4.9 Comparison of Methodology with Other Studies 
 
This investigation involves dosimetric evaluation of oncologist-defined structures on planning CT 
scans at every fifth fraction, therefore allowing regular assessment of the “actual” dose delivery as 
anatomical changes occur.Therefore a truly adaptive approach is implemented; as patients are 
treated with a re-optimised plan when dose delivery is assessed as suboptimal, within 24 to 48 
hours of the new planning CT scan. A subopimal dose delivery was defined using DVH assessment 
parameters, as described in section 3.4.5. 
Other published studies have reported an ART approach, whereby patients were treated with a re-
optimised plan during the course of radiation treatment for HNSCC. The frequency of re-imaging 
varies in these studies, with only two studies describing a weekly dose calculation protocol.  
In the study published by Schwartz et al (23), 24 patients underwent daily in-room CT scanning 
with weekly dose calculation and IMRT plan recalculation on contours generated using a 
deformable-image registration technique. However, in this current investigation, all contours are 
manually defined. The frequency of dosimetric evaluation by Schwartz et al is the same as in this 
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current investigation,however additional IMRT recalculation was performed if significant 
discepancies were found between the contour overlay on the daily CT scans and the treatment 
planning scan.  
Jensen et al (52) also report their protocol of weekly CT imaging. IMRT plan reoptimisation was 
only undertaken if there was >1 cm discrepancy between the target volume (specifically the CTV) 
or OAR contours on the newly aquired CT images and the original TV or OAR contours.  In other 
words, a decision to replan was based on an assessment of differences in contour overlay, rather 
than a dosimetric evaluation. Dosimetric assessment was subsequently performed retrospectively, 
but only on those patients who underwent a plan reoptimisation. Therefore, the question of 
whether assessment of contour overlay was an adequate alternative to prospectively performed 
dosimetric evaluation was not addressed in their study. 
The study by Ahn et al (18), describes imaging at three time points during the treatment course, at 
fractions 11, 22 and 33. Patients underwent replanning if there was inadequate target volume 
coverage (defined for the GTV, CTV and PTV structures) or if OAR constraints were not met. Wang 
et al (76), describe their protocol of a single re-imaging at fraction 25 in patients with 
nasopharyngeal tumours. All patients underwent IMRT plan recalculation and subsequent 
treatment with the reoptimised plan, regardless of TV and OAR coverage. Finally, the protocol 
described by Cheng et al (20) involves CT and MRI imaging at fractions 15 and 25 in patients 
treated for nasopharyngeal tumours. IMRT plan reoptimisation was undertaken if OAR doses 
exceeded  their tolerance doses or if target volume coverage was deemed unsatisfactory by the 
treating oncologist (these values are not defined in the paper).   
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CHAPTER 4 
 
General Results  
 
4.1 Patient Cohort 
 
Of the ten enrolled patients, nine were male. The mean age of the patient cohort was 63.7 years 
(range 49-82y).  
Patient characteristics are summarised in Table 4.1. Eight of ten patients had a diagnosis of 
oropharyngeal SCC; the remaining two patients had a diagnosis of nasopharyngeal and 
hypopharyngeal SCC. Two patients had early stage node-negative (T1N0) oropharyngeal SCC, and 
did not receive concurrent systemic therapy. Of the eight patients receiving concurrent systemic 
therapy, six were treated with weekly Cisplatin, and one was treated with weekly Cetuximab. 
Patient 6 was switched from Cisplatin to Cetuximab systemic therapy in the third week of 
radiotherapy due to the development of ototoxicity. Table 4.2 summarises the clinical outcomes of 
the patients; four patients remain alive and cancer–free. 
 
4.2 Adaptive Replanning 
 
A total of 84 CT scans were analysed. Six patients had a total of eight scans; the remaining four 
patients (Patients 6 to 9) had a total of nine scans. This was due to a protocol amendment (as 
described in section 3.4.1) to include a CT scan obtained at fraction 1. A total of 22 plan adaptations 
were required.  
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All plan adaptation events were triggered due to inadequate PTV coverage, rather than 
unacceptable spinal cord dose. As described in section 3.4.5, parotid gland dose parameters were 
not used to trigger plan adaptation. 
 
Patient 
number 
Site TNM 
stage 
Concurrent 
Chemotherapy 
Total 
number of 
plan 
adaptations 
Adaptive plan 
timings (fraction  
number) 
1 Oropharynx T3N1M0 Cisplatin 1 10 
2 Nasopharynx T4N2M0 Cisplatin 2 10,20 
3 Hypopharynx T3N2M0 Cisplatin 1 10 
4 Oropharynx T1N0M0 Nil 0  
5 Oropharynx T4N2M0 Cisplatin 3 5,10,25 
6 Oropharynx T2N2M0 Cisplatin/Cetuximab 5 1,5,15,20,30 
7 Oropharynx T2N2M0 Cetuximab 3 15,25,30 
8 Oropharynx T3N2M0 Cisplatin 3 1,5,30 
9 Oropharynx T1N0M0 Nil 0  
10 Oropharynx T3N2M0 Cisplatin 4 15,20,25,30 
  
Table 4.1. Main patient characteristics and adaptive planning schedule.   
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Patient 
number 
Alive (A) or 
Deceased (D) 
Cause of 
Death 
Recurrence 
 
Duration of 
Survival 
(yrs) 
Time to 
Recurrence 
(yrs) 
1 D O  1.88  
2 D C DR 1.32 0.52 
3 D  O*  2.25  
4 D O  2.70  
5 A   8.62  
6 A   7.84  
7 A   7.25  
8 D C DR 0.98 0.34 
9 A   6.52  
10 D C LR 0.72 0.00 
 
Table 4.2. Patient survival outcomes. 
C- Cancer, O- Other cause, LR- Local Recurrence, RR- Regional Recurrence, DR- Distant Recurrence. 
*- deceased due to a different cancer 
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4.2.1 Plan Adaptation Timing and Frequency 
 
The timing of adaptive replanning in each patient is shown in Table 4.1. Two patients (patients 4 
and 9) required no treatment plan adaptation during the course of radiotherapy; both had a 
diagnosis of early stage node-negative oropharyngeal SCC. 
 Of the four patients (patients 6 to 9) that underwent an additional CT scan at fraction one, two of 
them (patients 6 and 8), required adaptation of their treatment plan at fraction one, due to 
significant anatomical change resulting in unacceptable dose delivery to the PTV. The number of 
days between planning CT and fraction one of treatment was 20 days for patient 6 and 13 days for 
patient 8. By contrast, the delay between the planning CT scan and fraction one was 14 days for 
patient 7 and 27 days for patient 9. Despite a longer than usual delay for patient 9, the fact that they 
had early stage node-negative disease probably explains why plan adaptation was not triggered at 
fraction one.  
The mean number of plan adaptations for the patient cohort was two (range 0-5). Figure 4.1 and 
Table 4.3 demonstrate the timing of plan adaptations throughout the treatment course. Nine (41 %) 
plan adaptations were required at or before fraction 10; whilst 12 (55 %) of the total 22 plan 
adaptations occurred by fraction 15. All first plan adaptations and half of the second plan 
adaptations had occurred by fraction 15. Four patients also underwent plan adaptations at fraction 
30, just days before the end of a 35 fraction course of radiation therapy. 
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Figure 4.1. Timing of adaptive replanning, for first, second and subsequent plan adaptations 
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Fraction 
number 
Number of 
plan 
adaptations 
Percentage 
of total 
plan 
adaptations 
(%) 
Cumulative 
percentage of total 
plan adaptations 
(%) 
1 2 9.1 9.1 
5 3 13.6 22.7 
10 4 18.2 40.9 
15 3 13.6 54.5 
20 3 13.6 68.2 
25 3 13.6 81.8 
30 4 18.2 100.0 
Total 22 99.9  
 
 
Table 4.3. Frequency of weekly plan adaptations 
 
4.3 Weight and Nutritional Score 
 
4.3.1 Weight Loss and the Need for New Bolus or Immobilisation Mask 
 
The weekly mean weight change for the patient cohort is shown in Figure 4.2. The mean weight loss 
during treatment for all patients was 5.6 kg (range 0.3 to 10.0kg).  
Two patients (patients 2 and 6) required the making of new immobilisation masks; both at fraction 
20, due to a clinical evaluation revealing the existing mask to be too loose. Both of these patients 
also required adaptive replanning at this stage, due to unacceptable dose to PTV. The weight loss of 
these two patients at fraction 20 was 6.2 kg and 6.8 kg; double the mean weight loss of 3.1 kg 
(range +0.8 kg to -6.8 kg) of all ten patients at this time.  
Three patients (patients 6, 7, 10) required the addition of bolus material to fill air gaps between the 
immobilisation mask and skin. The gaps were not considered large enough to require a new 
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immobilisation mask. In all instances, the addition of bolus material was also accompanied by an 
adaptive replanning event, due to unacceptable PTV dose. For patient 6, new bolus material was 
added at fraction 15. Patient 6 subsequently had a new immobilisation mask made five fractions 
later as described above. Patient 7 had new bolus material added at fractions 15 and 25; patient 10 
received additional bolus material at fraction 25. 
5 10 15 20 25 30 35 40
0
5
10
15
20
0
1
2
3
4
5
6
7
8
Figure 1: Patient weight loss and PGSGA score
Fraction number
Mean PGSGA score
Mean weight loss (kg)
Pl 1
 
Figure 4.2. Mean patient weight loss and PGSGA score during treatment 
Pl- on RT planning day 
 
4.3.2 Change in Nutritional Score 
 
Nutritional status was measured using the PG-SGA assessment as described in section 3.4.6. The 
mean PG-SGA score increased during the treatment period (Figure 4.2), indicating worsening 
nutritional status. The weekly mean PG-SGA score and PG-SGA category is shown in Table 4.4. At 
the time of radiotherapy planning, the mean PG-SGA score was 5 (range 1-11) compared to a score 
of 17 (range 11-28) at fraction 35. There are three PG-SGA categories (A, B, C); where A is the best 
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nutritional category and C the worst. There was also deterioration in PG-SGA category between 
planning and at fraction 35. At the time of radiotherapy planning, all patients scored in Category A. 
At fraction 35, most patients were now in category B.  
 
Fraction 
number 
Mean PG-
SGA score 
Number of patients in each PG-SGA 
category 
  Cat A Cat B Cat C 
Planning 5 10 0 0 
5 9 7 3 0 
10 11 5 5 0 
15 15 2 8 0 
20 16 1 9 0 
25 15 2 8 0 
30 16 1 9 0 
35* 17 1 7 1 
 
 
Table 4.4. Mean PG-SGA score and PG-SGA category frequency for the patient cohort.  
*- missing data from patient 10. 
 
4.4 Correlation with Plan Adaptation Requirement 
 
There was no correlation found between the change in weight and the change in PTV70 coverage; 
correlation coefficient -0.135 (p=0.256). Similarly, there was no correlation found between the 
change in patient PG-SGA score and change in PTV70 coverage; correlation coefficient -0.046 
(p=0.703).  
There was a significant correlation found between change in weight and change in PG-SGA score; 
correlation coefficient 0.909 (p=0.002). This correlation can be seen in Figure 4.2, where the lines 
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of patient weight loss and PG-SGA score are practically parallel. This correlation is not completely 
surprising, as the PG-SGA score is derived from a number of factors, one of which is weight.  
In addition, it was found that larger initial nodal volumes correlated with a higher number of plan 
adaptations required throughout the treatment course, as shown in Figure 4.3. The Pearson’s 
correlation coefficient was 0.708 (p=0.022). 
 
 
 
Figure 4.3. Patient initial nodal volume vs. total number of plan adaptations required 
 
4.5 Overall Time for Target Delineation and Planning Processes 
 
It took approximately one hour for CT scan acquisition, rigid registration and dose recalculation. 
The subsequent delineation of contours took a median time of 240 minutes (range 210-270) for the 
original planning CT scan, and 180 minutes (range 80-270) for subsequent scans. The 
reoptimisation of treatment plan, dosimetry and Quality Assurance procedures were not measured 
for this investigation, but took approximately one working day to complete.   
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Chapter 5 
 
Anatomical Changes Observed during H+N 
IMRT 
 
5.1 Volumetric Changes in Target Volumes 
 
As described in Section 3.4.3, the GTVp, GTVn, CTVp, CTVn and CTVn0 were delineated manually. 
The PTV70 and PTV60 were created as an expansion of the relevant CTV volumes.  
  
5.1.1 Full Patient Cohort 
 
All Target Volumes, with the exception of the CTVn0 and PTV60 exhibited volume reduction over 
the treatment period, with significant reduction by fraction 35. The mean weekly volumes of these 
target volumes is summarised in Table 5.1. The GTVp reduced in volume from fraction 10, whereas 
a significant volume reduction in GTVn was not demonstrated till fraction 20. By fraction 35, the 
mean volume reduction was 25 % for the GTVp, 44 % for GTVn, 18 % for CTVp, 28 % for CTVn and 
11 % for the PTV70. 
The CTVn0 and PTV60 did not demonstrate significant volume change, which reflects the method 
by which the CTVn0 is delineated. The CTVn0 is the “non-muscle, non-bone” soft tissue space where 
at-risk, but non-visible, lymph nodes are situated. Logically, this soft tissue space would not be 
expected to reduce in volume as much as target volumes that are based on the presence of visible 
tumour (i.e. the CTVp and CTVn). The CTVn0 forms the majority volume of PTV60 construct; the 
other smaller components being the CTVp and CTVn. Therefore, it is reasonable that the PTV60 
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would not demonstrate significant volume reduction by fraction 35 given the relatively stable 
volume of the CTVn0. 
 
5.1.2 Patients with CT Scan at Fraction One 
 
Due to a protocol amendment, four of the ten patients underwent an additional CT scan at fraction 
one. The volumetric change of the TVs between planning CT and fraction one is shown in Table 5.2.  
There was an increase in tumour volume (GTVp and GTVn) between planning CT and fraction one; 
the GTVn increased more than the GTVp. Patients 6 and 8 required plan adaptations at fraction one. 
A larger increase in PTV70 and PTV60 volumes was observed in these patients, compared to the 
two patients who did not require plan adaptation. It would seem reasonable that, with a greater 
volume increase in the PTVs, the initial isodose distributions would not cover the subsequently 
larger PTVs at fraction one; therefore necessitating a plan adaptation at this stage.  
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Fraction 
number 
GTVp 
volume (ml); 
Volume 
change (%) 
P 
value 
GTVn 
volume (ml); 
Volume 
change (%) 
P 
value 
CTVp 
volume (ml); 
Volume 
change (%) 
P 
value 
CTVn 
volume (ml); 
Volume 
change (%) 
P 
value 
CTVn0 
volume (ml); 
Volume 
change (%) 
P 
value 
PTV70 
volume (ml); 
Volume 
change (%) 
P 
value 
PTV60 
volume (ml); 
Volume 
change (%) 
P 
value 
Planning 21.5 ±15.0  16.4 ±9.9  51.2 ±29.5  48.4 ±22.7  171.7 ±51.7  162.7 ±81.1  480.6 ±109.6  
5 22.0 ±16.0; 1.7 ±5.6 0.38 
16.2 ±11.6; 
-3.5 ±28.6 0.89 
51.8 ±27.6; 
3.9 ±14.7 0.69 
48.5 ±25.4; 
2.9 ±27.7 0.97 
168.7 ±49.4; 
-1.2 ±5.7 0.33 
166.8 ±84.3; 
2.5 ±10.7 0.49 
485.1 ±100.0; 
1.4 ±4.5 0.51 
10 20.1 ±15.4; -10.3 ±10.9 0.02 
14.2 ±9.1; 
-6.5 ±33.2 0.14 
47.9 ±27.1; 
-5.0 ±12.9 0.07 
45.4 ±20.7; 
-2.6 ±18.9 0.19 
173.6 ±48.6; 
2.2 ±10.2 0.72 
157.6 ±78.2; 
3.6 ±7.0 0.18 
476.7 ±100.5; 
-0.4 ±4.7 0.56 
15 18.5 ±15.1; -17.1 ±18.6 0.05 
13.2 ±9.3; 
-10.9 ±43.3 0.09 
47.3 ±29.9; 
-7.8 ±16.3 0.07 
43.7 ±21.4; 
-7.4 ±17.1 0.10 
168.5 ±57.0; 
-2.3 ±6.3 0.43 
152.6 ±77.7; 
-7.1 ±8.6 0.03 
471.2 ±113.4; 
-2.0 ±5.8 0.33 
20 18.2 ±14.8; -21.1 ±17.8 <0.01 
11.1 ±7.9; 
-24.7 ±39.9 0.03 
45.4 ±26.1; 
-10.6 ±12.7 0.01 
38.7 ±19.0; 
-15.6 ±26.1 0.03 
167.3 ±52.4; 
-2.1 ±7.9 0.37 
145.9 ±74.0; 
-10.2 ±12.0 0.02 
465.5 ±93.6; 
-2.5 ±6.0 0.15 
25 17.9 ±14.9; -22.8 ±20.6 <0.01 
9.9  ±7.4; 
-32.9 ±35.9 0.02 
46.5 ±27.7; 
-8.3 ±15.4 0.09 
37.1 ±19.4; 
-21.5 ±20.4 0.02 
166.3 ±51.1; 
-2.5 ±8.3 0.31 
148.1 ±77.2; 
-8.5 ±11.7 0.03 
466.4 ±99.0; 
-2.4 ±6.5 0.19 
30 17.0 ±13.6; -26.0 ±19.4 <0.01 
9.4  ±7.1; 
-37.0 ±31.7 0.02 
47.6 ±28.4; 
-6.4 ±18.1 0.14 
36.0 ±19.3; 
-24.7 ±20.0 0.02 
164.8 ±49.9; 
-3.2 ±9.8 0.22 
147.4 ±76.4; 
-8.6 ±15.2 0.06 
464.9 ±103.2; 
-2.9 ±5.9 0.11 
35 18.7 ±14.9; -24.6 ±22.9 <0.01 
9.1  ±7.6; 
-44.3 ±25.0 0.03 
47.1 ±30.4; 
-18.0 ±32.1 0.05 
35.5 ±19.6; 
-28.1 ±19.8 0.03 
162.9 ±54.1; 
-2.0 ±9.5 0.44 
143.8 ±77.7; 
-10.9 ±12.8 0.04 
459.3 ±108.2; 
-2.6 ±5.8 0.17 
 
Table 5.1. Mean volume (+ standard deviation) of target volumes during radiation treatment. Volume changes measured against the 
planning volume. 
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Target 
Volume Patient 
Volume at 
Planning 
(ml) 
Volume at 
Fraction 0 
(ml) 
Volume 
change 
(ml) 
Volume 
change 
(%) 
GTVp 
#6 11.85 12.41 0.6 4.7 
#7 18.06 18.29 0.2 1.3 
#8 13.36 14.36 1.0 7.5 
#9 8.60 8.94 0.3 4.0 
GTVn 
#6 18.05 22.79 4.7 26.3 
#7 28.17 29.56 1.4 4.9 
#8 22.67 24.07 1.4 6.2 
#9 0 0 - - 
CTVp 
#6 24.81 32.33 7.5 30.3 
#7 53.64 49.69 -4.0 -7.4 
#8 28.53 30.47 1.9 6.8 
#9 26.41 25.66 -0.8 -2.8 
CTVn 
#6 50.21 60.57 10.4 20.6 
#7 75.06 79.70 4.6 6.2 
#8 52.17 56.94 4.8 9.1 
#9 0 0 - - 
CTVn0 
#6 137.00 126.35 -10.7 -7.8 
#7 112.36 113.93 1.6 1.4 
#8 102.93 103.99 1.1 1.0 
#9 153.97 145.33 -8.6 -5.6 
PTV70 
#6 155.09 183.40 28.3 18.3 
#7 237.82 239.29 1.5 0.6 
#8 153.77 168.89 15.1 9.8 
#9 55.88 54.34 -1.5 -2.8 
PTV60 
#6 416.41 450.81 34.4 8.3 
#7 474.27 483.48 9.2 1.9 
#8 367.65 388.34 20.7 5.6 
#9 376.03 365.67 -10.4 -2.8 
 
Table 5.2. Volume changes in TVs of patients who underwent CT imaging at fraction one. 
Patient 9 had no suspicious or enlarged LN, therefore does not have the GTVn or CTVn 
defined.  
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5.2 Volumetric Changes in Salivary Glands 
 
5.2.1 Parotid Glands 
 
The parotid glands demonstrated a reduction in volume from the start of treatment, 
with a significant volume loss demonstrated commencing at fraction five. Mean parotid 
gland volume change is demonstrated in Table 5.3. At fraction 35, the mean parotid 
gland volume had significantly reduced by 7.09 ml (range 0.82 – 17.44 ml) or 28.0 % 
(range 4.3 – 45.3 %, p <0.01). This translates to a volume reduction of 0.20 ml or 0.8 % 
per day. 
 
5.2.2 Submandibular Glands 
 
The submandibular glands demonstrated a reduction in volume from the start of 
treatment. As with the parotid glands, a significant volume loss was demonstrated 
commencing at fraction five. Mean submandibular gland volume change is 
demonstrated in Table 5.4. Mean submandibular gland volume reduction was 2.10 ml 
(range 0.30 – 4.05 ml) or 25.7 % (range 3.1 – 46.4 %, p <0.01) at fraction 35. This 
translates to a volume reduction of 0.06 ml or 0.7 % per day, which is similar to the 
magnitude of parotid gland volume loss.
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Table 5.3. Mean Parotid Gland (right and left) volume, with standard deviation, during the treatment period. Volume reduction is compared to planning 
volume.
Fraction Planning 5 10 15 20 25 30 35 
Mean volume 
(ml) 
25.29 24.03 23.03 21.57 20.64 19.33 18.66 18.20 
Standard 
deviation (ml) 
6.16 5.60 5.27 4.63 4.59 4.49 3.78 4.13 
Volume 
reduction (ml)  
1.26 2.26 3.73 4.65 5.97 6.64 7.09 
Volume 
reduction (%) 
 4.98 8.94 14.75 18.39 23.61 26.26 28.0 
Weekly 
reduction (%) 
 4.98 3.96 5.81 3.64 5.22 2.65 1.74 
p value  
0.02 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
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Table 5.4. Mean Submandibular Gland (right and left) volume, with standard deviation, during the treatment period. Volume reduction is compared to 
planning volume. 
Fraction Planning 5 10 15 20 25 30 35 
Mean volume 
(ml) 
8.16 7.67 7.18 6.65 6.29 6.01 5.95 6.06 
Standard 
deviation (ml) 
1.54 1.49 1.51 1.38 1.46 1.65 1.63 1.78 
Volume 
reduction (ml)  
0.48 0.98 1.50 1.87 2.14 2.21 2.10 
Volume 
reduction (%) 
 5.88 12.01 18.38 22.92 26.23 27.08 25.73 
Weekly 
reduction (%) 
 5.88 6.13 6.37 4.54 3.31 0.85 -1.35 
p value 
 
0.02 <0.01 <0.01 <0.01 <0.01 <0.01 <0.01 
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5.3 Positional Changes in Salivary Glands 
 
5.3.1 Parotid Gland 
 
Table 5.5 demonstrates the movement of the parotid glands over the IMRT course. The 
movement of the whole parotid gland was measured using two different methods. 
Firstly, the relative shift of the COM of the gland relative to the COM position on the 
planning CT scan was measured in the x, y and z planes. The second method calculated 
the distance between the COM of the right and left parotid glands in the medial/lateral 
plane and then determined whether this distance changed relative to the distance on the 
planning CT scan. A smaller distance would indicate that the parotid glands had shifted 
medially and were therefore closer together. Neither of these methods demonstrated 
any significant displacement of the parotid gland relative to the planning CT scan.  
The relative movement of the lateral border of the parotid gland was also measured, by 
calculating the distance between the lateral border and the COM of the parotid gland 
(Table 5.5). The lateral border of the parotid glands demonstrated a significant medial 
shift at fractions 30 and 35. At fraction 35, there was a medial shift of 1.2 mm (range -0.1 
to 3.4 mm; p=0.02); although the centres of mass of the whole parotid gland did not shift 
medially (p=0.65).  
 
  
  
 
73 
 
   Medial-
lateral 
shift 
(mm) # 
p 
value 
Anterior-
posterior 
shift 
(mm) $ 
p 
value 
Superior-
inferior 
shift 
(mm) ^ 
p 
value 
Centre Of 
Mass 
change 
Planning 0.0  0.0  0.0  
5  -0.2 0.55 -0.2 0.70 0.1 0.83 
10  -0.1 0.65 0.6 0.30 -0.2 0.78 
15  -0.5 0.21 0.3 0.36 -0.2 0.77 
20  0.2 0.72 0.3 0.61 0.0 0.97 
25  -0.1 0.84 0.0 0.92 -0.1 0.83 
30  0.2 0.64 0.1 0.83 0.0 0.94 
35  -0.3 0.65 -0.2 0.81 0.0 0.98 
           
   Change 
in 
distance 
(mm) @ 
p 
value 
Change in 
medial-
lateral 
distance 
between R 
and L 
Centre Of 
Mass 
Planning 0.0  
5  1.9 0.50 
10  1.3 0.63 
15  1.0 0.27 
20  -0.3 0.75 
25  0.2 0.88 
30  -0.5 0.66 
35  0.4 0.41 
           
   Change 
in 
distance 
(mm) @ 
p 
value 
      
Change in 
position of 
lateral 
edge 
Planning 0.0        
5  -0.2 0.69       
10  0.2 0.58       
15  0.4 0.39       
20  0.8 0.13       
25  0.7 0.16       
30  1.1 0.03       
35  1.2 0.02       
 
Table 5.5. Parotid Gland movement, relative to position at planning CT scan, measured 
by different calculation methods. # positive value denotes a medial shift; $ positive value 
denotes an anterior shift; ^ positive value denotes an inferior shift. @ positive value 
denotes increased distance between the two points.  
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5.3.2 Submandibular Gland 
 
The movement of the whole submandibular gland was measured by calculating the 
relative shift of the COM of the gland relative to the COM position on the planning CT 
scan in the x, y and z planes. There was no significant shift of gland in the medial-lateral 
or anterior-posterior planes. However, a significant superior shift of the submandibular 
gland was observed at all fractions, except at fractions 20 and 35. At fraction 30, a 2.4 
mm superior shift (range -2.3 to 10.3 mm, p=0.02) was observed (Table 5.6).  
 
 Fraction 
number 
Medial-
lateral 
shift 
(mm) # 
p 
value 
Anterior-
posterior 
shift 
(mm) $ 
p 
value 
Superior-
inferior 
shift 
(mm) ^ 
p 
value 
Centre Of 
Mass 
change 
Planning 0.0  0.0  0.0  
5  0.4 0.44 -0.5 0.44 -1.6 0.036 
10  0.1 0.93 -0.8 0.60 -1.5 0.049 
15  -0.2 0.86 0.5 0.01 -1.7 <0.01 
20  0.1 0.94 0.5 0.96 -1.7 0.058 
25  0.2 0.83 0.8 0.51 -2.6 <0.01 
30  0.9 0.39 1.5 0.17 -2.4 0.021 
35  -0.3 0.74 -1.3 0.07 -1.3 0.206 
 
Table 5.6. Submandibular Gland movement, relative to position at planning CT scan. # 
positive value denotes a medial shift; $ positive value denotes an anterior shift; ^ 
positive value denotes an inferior shift.  
 
5.4 Volumetric Changes in Subcutaneous Fat 
 
The volume of fat was calculated on a single CT scan slice (at the isocentre level), as well 
as over larger number of slices (3, 5, 7 and 9) centred around the isocentre slice. There 
was a significant loss of fat volume seen in fractions 20, 25 and 35, only when measuring 
fat volume on a single CT scan slice (Table 5.7). By fraction 35, the volume of fat loss was 
1.9 mL or 24.9 % compared to the volume on the planning CT scan (Table 5.8). However, 
this result was not replicated when calculating fat volume on greater numbers of slices. 
Volume reductions were still observed, ranging from 12 and 13 %; but these results 
were not statistically significant. As the single isocentre slice is less likely to be 
representative of the entire fat volume, than when calculating on multiple CT scan slices, 
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the fat volume loss noted on a single CT scan slice is probably not a true representation 
of true fat volume changes.  
  
 
76 
 
Fraction 
number 
1 slice fat 
volume (ml) 
P value 
3 slice fat 
volume (ml) 
P value 
5 slice fat 
volume (ml) 
P value 
7 slice fat 
volume (ml) 
P value 
9 slice fat 
volume (ml) 
P value 
Planning 7.7 ±3.8 
 
29.2 ±14.3  48.8 ±23.6  68.3 ±32.4  87.9 ±40.9  
5 7.6 ±3.4 0.61 29.4 ±13.0 0.78 48.8 ±21.5 0.96 68.3 ±29.7 0.98 87.7 ±37.8 0.93 
10 7.1 ±3.3 0.12 28.0 ±12.2 0.26 47.0 ±20.2 0.29 66.3 ±28.0 0.35 85.9 ±35.9 0.42 
15 7.0 ±3.4 0.21 28.6 ±12.5 0.64 47.6 ±20.7 0.55 66.7 ±28.7 0.52 86.2 ±37.1 0.56 
20 6.6 ±3.2 0.11 27.8 ±12.3 0.35 46.4 ±20.4 0.31 65.1 ±28.3 0.29 83.7 ±35.8 0.26 
25 6.7 ±3.0 0.04 26.9 ±10.5 0.19 45.0 ±17.4 0.18 63.2 ±24.2 0.17 81.4 ±30.9 0.16 
30 6.0 ±2.5 0.01 26.6 ±9.7 0.07 44.5 ±16.4 0.06 62.4 ±23.0 0.06 80.4 ±29.9 0.05 
35 5.8 ±2.8 0.03 25.4 ±11.3 0.11 42.5 ±18.9 0.10 59.8 ±26.4 0.09 77.3 ±34.1 0.09 
 
Table 5.7 Mean volume (+ standard deviation) of fat during radiation treatment; measuring fat volume in different numbers of CT scan slices. 
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Reduction in volume 
between planning and 
fraction 35 
 
 Volume 
(mL) 
Percentage 
(%) 
P value 
1 slice fat 
volume (ml) 1.9 24.9 0.03 
3 slice fat 
volume (ml) 3.8 12.9 NS 
5 slice fat 
volume (ml) 
6.3 12.9 NS 
7 slice fat 
volume (ml) 
8.5 12.5 NS 
9 slice fat 
volume (ml) 
10.7 12.1 NS 
 
Table 5.8. Mean reduction in volume of fat during radiation treatment; measuring fat 
volume in different numbers of CT scan slices. NS- Non significant result. 
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Chapter 6 
 
Dosimetric Changes Observed during 
H+N IMRT 
 
6.1 Dosimetric Changes in Planning Target Volumes  
 
6.1.1 Original IMRT Plan 
 
There was a significant reduction in dose to both the PTV70 and PTV60 with the original 
IMRT plan, as shown in Figure 6.1. The reduction in dose to the PTV structures became 
significant from fraction five (Table 6.1). The mean V95 was less than 95 % for the 
PTV70 from fraction five onwards; and for the PTV60 from fraction 20 onwards. The 
results for fraction one were non-significant; however these data derive from only four 
patients (hence the wider 95 % confidence intervals) and therefore these data should be 
interpreted with caution.   
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Figure 6.1. Mean V95 coverage, with 95 % confidence intervals, of PTV70 and PTV60 for the original IMRT plan on weekly 
anatomy. Four patients only had data for fraction one. Pl- at RT planning.  
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Fraction number 
Mean V95 value 
of PTV70 (%) P value 
Mean V95 value 
 of PTV60 (%) P value 
Planning 97.4 ±2.0  98.0 ±1.0  
1 94.1 ±4.6 0.13 95.7 ±2.6 0.10 
5 93.2 ±4.8 0.02 96.2 ±2.1 <0.01 
10 91.9 ±4.7 <0.01 96.0 ±2.3 <0.01 
15 90.4 ±6.9 <0.01 95.5 ±3.0 0.01 
20 89.8 ±8.9 0.02 94.0 ±3.9 0.01 
25 88.6 ±8.3 <0.01 93.9 ±3.1 <0.01 
30 87.8 ±11.6 0.02 94.0 ±3.8 0.01 
35 90.6 ±8.4 0.03 94.1 ±3.2 <0.01 
 
Table 6.1.  Mean PTV coverage (+ standard deviation) of the Planning Target Volumes 
(PTV70 and PTV60) with original IMRT plan. Four patients only had data for fraction 
one. 
 
6.1.2 IMRT Plan Adaptation 
 
IMRT plan adaptation significantly improved both PTV70 coverage (overall p value of 
0.0004) and PTV 60 coverage (overall p value of 0.0012), as shown in Figure 6.2. Table 
6.2 demonstrates the weekly PTV70 and PTV60 coverage for the original treatment plan 
on the weekly anatomy (as if no plan optimisation was performed throughout the whole 
treatment) and for the adaptive planning strategy (one or more IMRT plan 
optimisations) in the patient cohort. When calculated weekly, the significant 
improvement with ART was seen for fractions 10 to 30 for the PTV70; and fractions 20 
to 35 for the PTV60.  
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 Mean V95 value of 
PTV70 (%) 
 Mean V95 value of 
PTV60 (%) 
 
Fraction 
number 
Original 
IMRT plan 
Adaptive 
strategy 
P value Original 
IMRT 
plan 
Adaptive 
strategy 
P value 
Planning 97.4 ±2.0   98.0 ±1.0   
1 94.1 ±4.6 97.8 ±0.5 0.164 95.7 ±2.6 97.4 ±1.1 0.264 
5 93.2 ±4.8 95.6 ±4.5 0.256 96.2 ±2.1 97.0 ±2.1 0.404 
10 91.9 ±4.7 97.1 ±3.0 0.009 96.0 ±2.3 97.6 ±1.1 0.061 
15 90.4 ±6.9 96.9 ±1.9 0.009 95.5 ±3.0 97.2 ±1.0 0.100 
20 89.8 ±8.9 96.2 ±3.5 0.048 94.0 ±3.9 97.5 ±1.5 0.019 
25 88.6 ±8.3 95.3 ±4.3 0.036 93.9 ±3.1 97.3 ±1.4 0.005 
30 87.8 ±11.6 95.9 ±4.3 0.055 94.0 ±3.8 97.9 ±1.2 0.006 
35 90.6 ±8.4 95.3 ±5.7 0.184 94.1 ±3.2 97.5 ±1.4 0.010 
 
Table 6.2. Mean PTV coverage (+ standard deviation) of original plan versus adaptive 
planning strategy during radiation treatment. Four patients only had data for fraction 
one. 
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Figure 6.2. Mean V95 coverage, with 95 % confidence intervals of (a) PTV70 and (b) 
PTV60, for the original treatment plan on weekly anatomy vs. adaptive planning 
strategy. Four patients only had data for fraction one. 
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6.2 Dosimetric Changes in Parotid Glands  
 
6.2.1 Original IMRT Plan 
 
The parotid gland dose is measured in terms of V26 for this investigation; i.e. the volume 
of the gland (in percentage value) receiving >26 Gy. There was a significant reduction in 
mean dose to the parotid glands with the original IMRT plan, with the exception of 
fractions one and 20 (Table 6.3). The data for fraction one derive from only four 
patients. 
 
Fraction 
number 
Mean V26 (%) P value 
Planning 40.6 ±15.6  
1 47.5 ±12.1 0.15 
5 37.1 ±17.9 0.01 
10 37.0 ±17.5 0.03 
15 36.2 ±16.7  0.01 
20 37.0 ±17.8 0.08 
25 33.9 ±16.4 0.01 
30 35.6 ±16.8 0.02 
35 33.5 ±15.5 0.03 
 
Table 6.3. Mean V26 (+ standard deviation) of parotid glands with original IMRT plan. 
Four patients only had data for fraction one. 
 
6.2.2 IMRT Plan Adaptation 
 
In the 22 adaptive replanning events, the parotid gland V26 value with the original IMRT 
plan was compared to the V26 value obtained with adaptive replanning (Table 6.4).  
Although the adaptive plans met the original parotid gland dose constraints, the 
adaptive plan delivered a higher parotid gland dose compared to the original plan 
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(p=0.001). This was due to a less rigourous examination of parotid gland dose when 
undertaking IMRT plan optimisation at the time of plan adaptation. Less emphasis was 
placed on maximal possible reduction of parotid gland dose, in order to achieve a rapid 
turnaround time to commence a patient on the reoptimised IMRT plan.  
Further retrospective replanning was therefore undertaken, with optimisation 
parameters placing more importance on the parotid gland dose. This retrospective 
replanning was able to obtain improved PTV coverage as well as a reduced parotid 
gland dose (ART2 values in Table 6.4). The box and whiskers plot in Figure 6.3 
demonstrates this improvement; the retrospective replanning events are named 
“ART2”. 
 
 
Original plan 
V26 (%) 
ART1 V26 
(%) 
ART2 V26 
(%) 
Mean 37.8 43.54 34.29 
Standard 
Deviation 15.1 16.4 13.5 
P value  <0.01 0.01 
 
Table 6.4. Mean V26 values of parotid glands for all replanning events; comparing the 
original IMRT plan (Original) vs. adaptive replan (ART1) vs. retrospective replan 
(ART2). The p values compare the replans (ART1 and ART2) with the original IMRT 
plan. 
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Figure 6.3. Comparison of mean coverage of (a) Parotid Gland (V26) and (b) PTV70 
(V95)  for the original plan (Original) vs. the adaptive plan used for treatment (ART1) vs. 
the retrospective adaptive plan (ART2). The error bars represent the maximum and 
minimum values.   
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6.3 Dosimetric Changes in Spinal Canal  
 
6.3.1 Original IMRT Plan 
 
The spinal canal dose has been calculated in two ways. Firstly, the volume (in mL) of the 
contoured spinal canal receiving >45 Gy; secondly the maximum dose to the spinal canal 
(to a volume of 0.1 mL). There is no trend seen with how the dose to the spinal canal 
changes during treatment (Table 6.5). Whilst there were isolated significant results at 
fractions 10, 25 and 35; these results are insufficient to draw any conclusions.  The data 
for fraction one derive from only four patients. 
 
Fraction 
number 
Volume 
>45Gy (mL) 
 
P value Max dose 
(cGy) 
P value 
Planning 0.3 ±0.6  4691 ±983   
1 0.4 ±0.7 0.31 4761 ±558 0.25 
5 0.6 ±0.9 0.07 4809 ±652 0.54 
10 0.6 ±0.9 0.05 4898 ±904 0.01 
15 0.9 ±1.2 0.11 4974 ±686 0.06 
20 0.7 ±1.1 0.14 4793 ±557 0.67 
25 0.9 ±1.0 0.04 4980 ±644 0.24 
30 0.8 ±1.4 0.25 4709 ±565 0.96 
35 0.8 ±1.1 0.06 4982 ±812 <0.01 
 
Table 6.5.  Volume of spinal canal receiving >45 Gy and maximum dose to spinal canal (+ 
standard deviations) with original IMRT plan. Four patients only had data for fraction 
one. 
 
6.3.2 IMRT Plan Adaptation 
 
In the 22 adaptive replanning events, the spinal canal dose on the original IMRT plan 
was compared to the dose obtained with adaptive replanning (Table 6.6). There was a 
significant reduction in spinal canal dose with adaptive replanning, compared to the 
original IMRT plan; both in terms of volume of spinal canal receiving >45 Gy and 
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maximum spinal canal dose.  The maximum spinal canal dose with adaptive replanning 
was 5093 cGy compared to 5459 cGy with the original IMRT plan (p<0.01). 
 
 
Volume 
>45Gy, 
Original plan 
Volume 
>45Gy, 
Adaptive 
plan 
Max dose 
(cGy), 
Original plan 
Max dose 
(cGy), 
Adaptive 
plan 
Mean 0.9 0.4 5459 5093 
Std deviation 1.1 0.6 821 820 
P value  0.01  <0.01 
 
Table 6.6. Volume of spinal canal receiving >45 Gy and maximum dose to spinal canal for 
all 22 replanning events; comparing the original IMRT plan vs. adaptive replan. The p 
value compares the adaptive replan with the original IMRT plan. 
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Chapter 7 
 
Summary of Research, Discussion 
and Conclusions 
 
7.1 Restatement of Project Aims and Research Questions  
 
The two aims of this project were: 
Aim 1. Investigate the anatomical changes occurring in a cohort of patients during H+N 
radiotherapy. 
Aim 2. To investigate the impact of anatomical changes on dose delivery to the Target 
Volumes, parotid glands and spinal canal; and the impact of IMRT plan adaptation on 
subsequent dose delivery to these structures. 
The following research questions have addressed these aims: 
Aim 1. 
a. What volumetric changes are observed in the Target Volumes during H+N 
IMRT? 
b. What volumetric and geometric changes are observed in the parotid and 
submandibular glands during H+N IMRT? 
c. Are any changes in subcutaneous fat volume detectable during H+N IMRT? 
Aim 2. 
a. What doses are delivered to the PTVs, parotid glands and spinal canal during 
unadapted H+N IMRT? 
b. What is the impact of plan adaptation on the PTV dose, parotid gland dose 
and spinal canal dose? 
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c. Do any factors correlate as predictors of when the IMRT plan requires an 
adaptation? 
In answering these research questions, the goal has been to add to the body of 
knowledge on anatomical changes occurring within the head and neck region during 
head and neck cancer RT and to explore how ART may be best utilised to improve our 
treatment delivery in this cohort of patients. There is a balance to be gained between 
clinical gain and resource use, especially in terms of additional time spent in 
implementing ART by the various professionals involved in the RT process.  There is a 
willingness to embrace new technology in radiation therapy, and the implementation of 
new technology should be accompanied by a thorough quantitative investigation of its 
actual benefit. As a result of this project, it is hoped that further research questions can 
be generated and subsequently investigated.  
 
7.2 Summary of Research  
 
7.2.1 Volumetric Changes Observed in the Target Volumes 
during H+N IMRT 
 
The tumour volumes were demonstrated to reduce in volume over the treatment period, 
with the exception of the CTVn0 (representing the uninvolved, but at-risk nodal region) 
and the PTV60 (low dose PTV).  At fraction 35, the nodal volume (GTVn) had greater 
volume reduction (44 %) compared to the primary tumour volume (GTVp) (25 %).  It is 
hard to compare these results to the existing literature, as there is variation in the 
timings of when volumes are measured as well as which tumour volumes are measured 
(section 2.2). CT studies reporting primary tumour volume reduction at the end of RT 
report ranges of 17 to 80 % in volume reduction; results from this investigation fall 
within these parameters. 
Of the 4 patients who underwent an additional CT scan at fraction 1, an increase in 
tumour volume was observed between the planning CT scan and the start of treatment. 
For the two patients who needed plan adaptation at fraction one, there was a larger 
increase in tumour volume, which translated to larger increases in PTV volumes (both 
PTV70 and PTV60) compared to the two patients who did not need plan adaptation. 
This suggests that minimising the interval between treatment planning and 
commencement of treatment is important in some patients; emphasising the need for 
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adequate resources to ensure that the treatment planning process can proceed with 
minimal delay. 
 
7.2.2 Volumetric and Geometric Changes Observed in the 
Salivary Glands during H+N IMRT 
 
The parotid glands showed a volume reduction of 28 % by the end of RT; similar to the 
published average volume reduction of 26 % obtained from an analysis of multiple 
studies (48). Significant volume reduction was observed from fraction five. Whilst some 
authors report a greater volume reduction in the first half of treatment, compared to the 
second half, this investigation has not shown this trend. Comparison of ipsilateral versus 
contralateral parotid gland volume reduction has not been made in this investigation, as 
all patients received bilateral neck treatment. In terms of parotid gland shift, a small 
medial shift of 1.2 mm of the lateral portion of the gland was demonstrated by fraction 
35. The whole parotid gland did not demonstrate a significant shift. This is a smaller 
magnitude of shift than what is reported in the literature, as discussed in section 2.3.1. It 
could be accounted for by set-up uncertainties and averaging of geometric shifts in 
varying directions for different patients, discussed further in section 7.3.5.  
The submandibular glands demonstrated significant volume reduction from fraction 
five, with a total reduction of 26 % by the end of RT. Again, this is similar to the average 
volume reduction of 22 % acquired from pooling of data from multiple studies (48). A 
greater volume reduction was observed in the first half of treatment, compared to the 
second half of treatment; similar to other literature as discussed in section 2.3.2. An 
average superior shift of 2.4 mm for the submandibular glands was observed by fraction 
30 in this investigation; similar to what has been described by some other authors. 
However, the method used in this investigation for measuring submandibular gland 
movement was not as robust as the method used for measuring the parotid gland 
movement, as discussed in section 3.4.5. This is a limitation of this analysis and should 
be considered when interpreting the results. 
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7.2.3 Changes Observed in Subcutaneous Fat Volume during H+N 
IMRT  
 
There was a significant loss of fat volume seen in fractions 20, 25 and 35, when fat 
volume was measured on a single CT scan slice (Section 5.4). However, this result was 
no longer significant when calculating fat volume on greater numbers of slices. The fat 
volume loss noted on a single CT scan slice is unlikely to be an accurate representation 
of true fat volume changes; as the single isocentre slice is less likely to be representative 
of the entire fat volume. However, this section of the investigation is unique, as there is 
no published literature on fat volume changes during H+N RT. It is worth considering fat 
volume changes in future investigations, since weight loss during treatment would affect 
the amount of fat present. The loss of fat volume in the head and neck region may alter 
the positioning of the target volumes within the neck and hence impact dose delivery. 
 
7.2.4 Dose Delivery to PTVs during Unadapted and Adapted H+N 
IMRT 
 
A significant reduction in dose to the PTV70 and PTV60 was observed from fraction five; 
with unacceptable dose delivery to the PTV70 from fraction five and to the PTV60 from 
fraction 20. Plan adaptation resulted in a significant improvement in dose delivery to 
both the PTV70 and PTV60.  
The published literature is not consistent in reporting the dosimetric variations to 
tumour target volumes; with some authors reporting both underdosing of tumour 
volumes and increased dose homogeneity, whilst other authors report no underdosing 
to the tumour volumes. Similarly, the effect of plan adaptation on tumour volume 
coverage is also not consistently reported, with some authors reporting improved dose 
delivery and others reporting no improvement. The limitations of comparing the 
published literature on this aspect have been discussed in section 2.7.1. 
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7.2.5 Dose Delivery to Parotid Glands during Unadapted and 
Adapted H+N IMRT 
 
This investigation demonstrated a reduction in parotid gland dose (mean V26) if 
patients received unadapted treatment.  At planning, the mean V26 value for all parotid 
glands was 40.6 %; reducing to 33.5 % at fraction 35. This finding is different to what 
the literature in general has described; that unadapted treatment results in higher 
parotid gland dose than what was originally planned. Brouwer et al (48) report an 
average increase in mean dose of 2.2 Gy to the parotid glands. Only two other studies 
have demonstrated similar findings to this investigation, i.e. no increase in parotid gland 
dose delivery with unadapted treatment. In one study (31), most patients did not have 
nodal disease in the neck and in the other study (21), most patients had either received 
neoadjuvant chemotherapy to reduce bulky disease in the neck or had undergone a neck 
dissection prior to radiation therapy. Given this observation, the difference between the 
finding of this investigation and other published reports could be due to the differences 
in the extent of nodal disease between the patient cohorts. Other factors affecting dose 
delivery to the parotid glands could be differences in tumour site, beam arrangements 
or daily set-up variations; discussed further in section 7.3.5. 
In this investigation, although the adaptive plans met the original parotid gland dose 
constraints, the adaptive plan delivered a higher parotid gland dose compared to the 
original plan. This was because, in order to rapidly commence a patient on the 
reoptimised IMRT plan, less emphasis was placed on minimising parotid gland dose 
when undertaking plan adaptation. The first acceptable adaptive treatment plan in 
terms of PTV coverage was utilised. However, on retrospective replanning (ART2), it 
was demonstrated that plan adaptation could result in a reduction in the mean V26 of 
the parotid glands reduced parotid gland dose delivery (whilst still maintaining 
acceptable PTV dose delivery); consistent with other published literature. IMRT plan 
optimization parameters for the parotid glands should be adjusted for adaptive 
replanning, in order to keep the parotid gland dose below that for the original plan. 
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7.2.6 Dose Delivery to Spinal Canal during Unadapted and 
Adapted H+N IMRT 
 
There was no significant increase in spinal cord dose during H+N RT for the unadapted 
plans; though isolated significant increases were noted on 3 occasions. This differs to 
reports in the literature, with a general consensus that unadapted treatment results in 
the spinal cord receiving a higher dose than planned. Some investigators have also 
reported that a proportion of patients exceed the spinal cord tolerance doses (18,20) 
with unadapted treatment.  
In this investigation, IMRT plan adaptation resulted in reduced spinal cord dose (both 
volume receiving >45 Gy, and maximum spinal cord dose); which corresponds with 
other published reports. 
 
7.2.7 Correlations with Need for Plan Adaptation  
 
Whilst there was significant weight loss in the patient cohort during the treatment 
course, weight loss did not correlate with a change in PTV coverage. Nutritional status 
also deteriorated during the treatment course, as seen by an increase in the PG-SGA 
score. However, the nutritional score did not correlate with change in PTV coverage 
either. However, this investigation has a small number of patients and it is unlikely that 
any significant correlation would be identified. Further larger scale investigations would 
be required in order to examine this question further. 
However, a significant correlation between initial nodal volume and the number of plan 
adaptations was identified. It would make sense that patients with a higher volume of 
nodal disease in the neck would require more plan adaptations, as anatomical changes 
due to nodal shrinkage would lead to alterations in dose delivery within the neck. 
Numerous correlations with dose delivery to tumour structures and OARs have been 
investigated and results reported in the published literature. These investigations often 
involve small patient populations, with the identification of measures of plan 
inadequacy not being the primary objective of the study. Although some statistically 
significant findings are reported (Section 2.8.2), correlations are often weak and no 
single factor stands out from the numerous correlations reported. 
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7.3 Discussion  
 
This investigation raises issues worthy of discussion in several areas: 
i. The impact of an ART protocol on departmental resource allocation 
ii. The accuracy and consistency in contour delineation for weekly CT scans 
iii. The management of shrinking tumour volumes 
iv. The use of PTV or CTV for assessment of tumour dose delivery 
v. Interpretation of dosimetric results 
vi. Optimal frequency and timing of imaging and adaptive planning 
vii. Strengths and limitations of this investigation 
viii. Recommendations for an ART protocol 
ix. Potential future directions for research. 
 
7.3.1 Impact of this Protocol on Departmental Workflow and 
Resource Allocation 
 
The implementation of this ART protocol resulted in a significant change in how the 10 
enrolled HNC patients received their radiation treatment, compared to unenrolled HNC 
patients. The default departmental policy was to trigger re-imaging with a planning CT 
scan if the patient immobilisation mask was noted to be looser or contain large air gaps, 
or if there had been a significant reduction in clinically apparent nodal disease. 
Implementing the investigation protocol, using conventional planning CTs, required 
substantial additional resources, in terms of radiation oncologist, radiation therapist 
and physicist time. Therefore, the department embarked upon a steep learning curve in 
terms of optimising workflow and delivering this protocol in an efficient manner. 
In this investigation, the goal was to achieve a turnaround time of 24 to 48 hours for 
assessment of the treatment plan dose distribution and undertaking plan adaptation (if 
required). It took approximately one hour for CT scan acquisition, rigid registration and 
dose recalculation. The subsequent delineation of contours took a median time of 240 
minutes for the original planning CT scan, and 180 minutes for subsequent scans. By 
contrast, other publications report physician contouring times of between 44 to 150 
minutes (38,80,81,95). This timing can vary widely depending on the amount of 
structures contoured and physician experience. The reoptimisation of treatment plan, 
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dosimetry and Quality Assurance procedures were not measured for this investigation, 
but took approximately one working day to complete.  
With the first patient, the first adaptive plan could not be delivered within a 24 to 48 
hour turnaround time. However, within a short time, efficiency had improved and it was 
possible to re-contour, assess and perform plan adaptation (if required) within a 24 to 
48 hour turnaround time. By contrast, Schwartz et al report a median of two days (range 
one to four) from CT imaging to delivery of an adapted treatment plan (23). Achieving 
this turnaround time required good communication and co-ordination between the 
various staff members involved. However, the impact on staff time meant that the 
departmental resources allowed for only one patient at a time to be enrolled on the 
protocol. Clinical implementation of this protocol, involving weekly imaging and plan 
assessment, in all HNC patients was beyond the capability of the department. However, 
this exploratory protocol was important in helping to develop recommendations for 
implementing a more practical ART policy for all HNC patients. Additionally, the lessons 
learnt from undertaking this investigation meant that all subsequent H+N patients 
benefited, as the HNC RT planning process substantially improved in terms of planning 
time and techniques.  
 
7.3.2 Contouring Accuracy and Consistency 
 
The initial accuracy of TV definition is of major importance, since it can potentially affect 
patient clinical outcome. Peters et al (96) reported on the impact of radiotherapy quality 
on clinical outcome in a large international phase three study. Major deficiency in the 
treatment plan was associated with a 20 % reduction in overall survival.  Approximately 
one quarter of these major deficiencies were due to inadequate identification of the GTV. 
In this investigation, GTV definition on the initial planning CT scan used information 
acquired from clinical examination, as well as information from other imaging 
modalities such as the diagnostic CT scan, FDG-PET and MRI imaging.  
Consistency in weekly contouring was an essential component of this investigation, as 
the calculation of volume change and subsequent dose delivery to contoured regions 
relied on this. Therefore, all contours were manually performed by a single radiation 
oncologist, in order to eliminate interobserver variability, and validated by a second 
radiation oncologist. Intraobserver variability was minimised by adhering strictly to 
international consensus guidelines for contouring (88) and ICRU 62 definitions (89). 
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Following these guidelines and the ICRU definitions ensured that contouring was 
performed by adhering to anatomical boundaries, rather than a “Picasso approach” to 
contour generation. A formal assessment of intraobserver variability was not 
undertaken for this investigation. During the contour definition process on the initial 
planning CT scan, annotations of contour placement decisions were also made, to 
improve consistency in weekly contouring and further minimise intraobserver 
variability. This was especially useful when contouring the GTVp each week.  The use of 
annotations had the additional benefit of reducing weekly contouring time. 
Whilst the original planning CT scan utilised i.v. contrast; subsequent planning CT scans 
were non-contrast studies, in order to reduce inconvenience to the patient (of weekly 
intravenous access) and to reduce the risk of i.v. contrast-related reactions. It was more 
challenging identifying the tumour boundaries on a non-contrast CT scan, especially for 
the GTVp as there is less difference in CT density between the primary tumour and 
adjacent normal tissue (unless the tumour is adjacent to bone or air). However, the 
annotations of contouring placement decisions assisted significantly in the weekly 
contouring process, especially with respect to the primary tumour volume.  
 
7.3.3 Shrinking Tumour Volumes  
 
There is a lack of evidence about how to delineate a shrinking target volume during the 
course of RT. When the tumour shrinks, a reduction in treatment volume should reduce 
toxicity, but this is a futile gain if the reduction also results in recurrence. The CTV 
around a tumour is seemingly “uninvolved tissue” but may still contain large numbers of 
viable tumour cells. If alterations for a shrinking tumour are inadequate; tumour 
recurrence may result from inadequate radiation dose being delivered to areas of 
subclinical disease. In a recent publication by Hamming-Vrieze et al (43), eight patients 
with oropharyngeal tumours had fiducial markers implanted in the tissue at the 
periphery of the primary tumour. These fiducial markers were used as a surrogate to 
investigate the behaviour of tissue surrounding the GTV edge. Marker displacement 
relative to the GTV surfaces was examined using daily CBCT and MRI scans (at weeks 
three and six). The authors concluded that reducing the CTV volume mid-treatment (by 
following GTV reduction) risked under-dosing microscopic disease. They concluded that 
adjusting CTV volumes to “clear anatomical boundaries” was a safer approach to 
managing shrinking tumour volumes.  
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Hansen et al (42) described their approach to avoid under-treating microscopic disease, 
as the GTV shrinks. They maintained the original GTV volume on the second CT scan, 
with some modification to anatomical boundaries (such as air and skin) only. The 
second mid-treatment CTV volume was reported to decrease by 7.5 % due to weight loss 
and/or tumour and nodal shrinkage. Zhao et al (35) modified subsequent GTVs 
according to their shrinkage, but maintained the size of the original CTV contours. Other 
authors  describe their approaches where GTVs were modified to the air/tissue 
interface and CTV/PTV contours were generated by maintaining the original contours 
with adjustments at the skin surface or at boundaries with adjacent normal structures 
(24,59). Several  authors emphasise the importance of maintaining the prescribed dose 
to the pretreatment volumes (20,31,97,98), but without giving specific strategies for 
generating contours in the presence of shrinking tumour volumes. 
In this investigation, it was decided to delineate the CTVp volumes on the weekly CT 
scans according to clear anatomical boundaries, in order to reduce the risk of 
undertreating microscopic disease. As detailed above, this approach is now 
recommended in the publication by Hamming-Vrieze et al (43). In terms of delineating 
shrinking nodal volumes (CTVn), a different contouring approach was required as the 
nodes are located in the soft tissue, often with distant anatomical boundaries. Unlike the 
primary tumour volume, there is no evidence to guide the delineation of shrinking nodal 
volumes. Three different strategies were discussed prior to patient enrolment in this 
investigation. These strategies, summarised in Figure 7.1, were:  
i. Constant Expansion Margin 
This approach applies a constant 3 mm GTVn to CTVn expansion margin 
whenever the CTVn is generated. As the lymph node reduced in size, 
surrounding soft tissue would move inwards and be incorporated by the 
expansion margin. However, a smaller volume of soft tissue would be covered 
within CTVn as the lymph node reduced in size. 
ii. Fixed Expansion Position 
This approach applies a variable expansion margin so that there is a fixed CTVn 
margin position; resulting in a larger volume of soft tissue being incorporated 
into the CTVn volume as the lymph node reduced in size.   
iii. Fixed CTV Volume 
This approach calculated the non-GTVn CTVn volume and calculates a new 
expansion margin to maintain a fixed volume of soft tissue within the CTVn as 
the lymph node reduces in size.  This complex volumetric approach would 
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require an individualized margin for each node in each patient, as the rate of 
volume reduction could vary between nodes.   
 
 
 
Figure 7.1. Three options, considered for this investigation, for contouring shrinking 
nodal volumes (CTVn) on weekly imaging.  
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The first option was selected for this investigation; i.e. the CTVn was contoured each 
week by maintaining a 3mm margin around the visible lymph node (GTVn). This was felt 
to be a reasonable and practical approach, as all of the soft tissue surrounding the lymph 
nodes would be either a component of the CTVn or the CTVn0 (at risk area treated to 60 
Gy). The CTVn0, containing at risk soft tissue, was contoured according to anatomical 
boundaries on each weekly scan. 
Tumour shrinkage was noted as treatment progressed; with a significant volume 
reduction of 24.6 % in the GTVp and 44.3 % in GTVn (Table 5.1). The corresponding 
CTVp and CTVn volumes also reduced in volume. For the primary tumour, most of the 
18.0% reduction in CTVp volume was due to visible tumour volume reduction (Table 
7.1); the volume of surrounding soft tissue contributing to the CTVp (i.e. CTVp volume – 
GTVp volume) only reduced by 4.4 % by fraction 35. Therefore contouring a shrinking 
CTVp along anatomical boundaries resulted in a consistent volume of tissue 
incorporated in this contour.  
 
Fraction 
number 
Volume (ml) of normal tissue in 
CTVp 
[CTVp minus GTVp],  
Vol change from planning (%) 
Volume (ml) of normal tissue in 
CTVn  
[CTVn minus GTVn],  
Vol change from planning (%) 
Planning 29.7mL 32mL 
5 29.8, +0.3 32.3, +0.9 
10 27.8, -6.4 31.2, -2.5 
15 28.8, -3.0 30.5, -4.7 
20 27.2, -8.4 27.6, -13.8 
25 28.6, -3.7 27.2, -15 
30 30.6, +3.0 26.6, -16.9 
35 28.4, -4.4 26.4, -17.5 
 
Table 7.1. Volume change in soft tissue comprising CTV volumes over the treatment 
course.  
 
However, due to the different method for contouring shrinking nodal disease, the 
reduction in volume of soft tissue surrounding the lymph nodes (i.e. CTVn volume – 
GTVn volume) contributed to 17.5 % of the total 28.1 % volume reduction in CTVn 
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(Table 7.1). In other words, the 3 mm margin around the GTVn covered a smaller 
volume of soft tissue compared to the initial planning CT. The previously included soft 
tissue fell outside the CTVn boundary and therefore became a component of the CTVn0. 
The CTVn0 volume did not demonstrate a significant volume reduction as treatment 
progressed (Table 5.1).  
Whilst the clinical impact of the method used in this investigation for contouring 
shrinking nodal volumes cannot be compared to other investigations, it is worth noting 
that no nodal recurrences were observed in follow up of the patient cohort. However, 
the management of contouring shrinking nodal and primary tumour volumes in an area 
worthy of further investigation. 
 
7.3.4 The Use of PTV or CTV for Assessment of Tumour Dose 
Delivery  
 
This investigation used the PTV volumes (PTV70, PTV60) to assess the adequacy of dose 
delivery to the tumour and as a trigger for plan adaptation. There is a difference in 
opinion amongst radiation oncologists as to whether the PTV or the CTV is the most 
appropriate structure for an assessment of tumour dose delivery. 
The CTV is a biological construct, which describes the extent of microscopic tumour 
spread beyond the visible tumour (GTV). The CTV is defined according to boundaries 
between different tissue planes and incorporates a clinical assessment of the risk and 
extent of microscopic spread based on pathological data. The PTV, by contrast, is a 
geometric construct incorporating the CTV, which accounts for random and systematic 
uncertainties in treatment delivery (set-up margin) as well as a margin for tumour 
motion (internal margin). Unlike the CTV, the PTV cannot and should not be adjusted 
according to clinical circumstances (e.g. patient anatomy where a critical OAR is in close 
proximity). The ICRU62 (89) recommends that radiotherapy dose is prescribed to the 
PTV and the PTV should be used when reporting dose delivery. Therefore, it makes 
sense that if the PTV is the volume that is used to determine whether the initial 
treatment plan is suitable; it should also be the volume used to assess the ongoing 
suitability of the treatment plan. This is the rationale behind the use of PTV dose to 
determine the need for plan adaptation in this investigation. Other authors have also 
described dose to the PTV (11,18,20,24–27,40,42,58); as described in sections 2.4 and 
2.7.1. Ahn et al (18) report their TV and OAR parameters which triggered plan 
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adaptation. The PTV parameters were identical to the parameters used in this 
investigation, i.e. D95 <95 % of the prescription dose.  
The selection of PTV margin is based on departmental data as per institutional IGRT 
protocol. This was determined via a prior departmental investigation and implemented 
for all Head and Neck cancer patients. The PTV margin used for this investigation is 
similar to the margin used by Schwartz et al (23,77). However, Schwartz et al used a 
0mm margin for PTV contour generation on the rescans. The 3mm margin, for weekly 
PTV contour generation, used in this investigation is a conservative margin in 
comparison. The selection of PTV margin is further supported by other investigators 
(40,99), whereby a 3mm margin for PTV generation was not inferior to a 5mm in terms 
of clinical outcome or target volume dose coverage.  
 
7.3.5 Interpretation of Dosimetric Results  
 
Whilst dose calculation on repeat imaging studies is performed and reported widely, 
interpretation of the data needs to consider causes for variability in the results. Some 
variability between studies may be due to differences in the patient population (for 
example, disease site and staging) or treatment factors, such as variations in beam 
arrangement and whether RT is delivered post-operatively or in the definitive setting, 
without or without neoadjuvant or concurrent chemotherapy. Robar et al (ref 58) and 
Hansen et al (ref 42) report that parotid gland dose changes were not consistent 
between the right and left parotid glands. In the investigation by Robar et al (ref 58), 
there was significant increase in dose delivery to the parotid gland on the left side only. 
They suggest that this variability could arise due to differences in tumour location and 
size, or due to IMRT beam arrangements. Rotational set-up errors could also account for 
these variations, as discussed later in this section.  Other differences in the patient 
population may arise due to the movement of interstitial fluid, resulting in tissue 
deformation. This could impact dose delivery and may vary during treatment (85). 
Kagar at al (54) report the parotid gland displacement due to pre-chemotherapy 
hydration; with a lateral displacement seen in the immediate days following 
chemotherapy administration and a medial displacement observed thereafter. 
This investigation demonstrated a reduction in parotid gland dose (mean V26) during 
the course of radiation therapy if patients had received unadapted treatment.  This 
finding is different to what the literature in general has described (as discussed in 
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section 2.5.1); that unadapted treatment results in higher parotid gland dose than what 
was originally planned. In this investigation, two of 10 patients had no visible nodal 
disease in the neck. Given this observation, the difference between the finding of this 
investigation and other published reports could be due to the differences in the extent of 
nodal disease between the patient cohorts. Similar to this investigation; two studies 
(21,31) also reported no increase in parotid gland dose.  In the investigation by Height 
et al (31), only four of 10 patients presented with lymph node disease in the neck; other 
studies tend to report greater numbers of patients with nodal disease. Similarly, in the 
study by Ho et al (21), the majority of patients had either received neoadjuvant 
chemotherapy to reduce bulky disease in the neck or had undergone a neck dissection 
prior to radiation therapy and therefore had reduced nodal disease. It is quite plausible 
(though not conclusively demonstrated by these 2 studies) that the extent of nodal 
disease could result in variability in dose reporting to the parotid glands.  
Variability in contour delineation may introduce variations in dose deposition. Feng et al 
(100) studied the dosimetric impact of contouring variability in OARs in the H+N. A 
mean difference of 0.9 Gy (range 0.6- 1.1Gy) was reported due to the spatial differences 
in contour generation between different observers. With respect to tumour volumes in 
the H+N, contouring variability has been reported (101), however there is no data 
reporting the dosimetric impact of this variability. In this investigation, contouring 
variability was minimised by using a single observer to perform all contour generation, 
with a second observer to check the subsequent contours. Additionally, the image 
registration process may introduce random and systematic variability, which could 
impact on results of contour shift and dosimetric comparison (102).  
Interfraction positional variation of the patient also has a significant effect on dose 
delivery; the magnitude of which is reduced with daily imaging and set-up corrections 
(103). Siebers et al (104) reported dose deviations to the GTV of ≥ 3 % in 11 % of their 
HNC patient sample as a result of random and systematic errors in patient set-up; 
though only 2 % of the patient sample had dose deviations of ≥ 5 %. Delana et al (105) 
quantified the impact of set-up variations on parotid gland dose. A 3 % increase in mean 
parotid dose was observed with each millimetre displacement in the craniocaudal and 
lateral dimensions; displacements in the anteroposterior dimension had a smaller 
impact. Ahn et al (18) report significant correlations between positional variation and 
dose delivery to parotid glands, target volumes, spinal cord and mandible. Han et al (49) 
demonstrated an increase in spinal cord Dmax of up to 0.5 Gy if daily set-up corrections 
were not undertaken. Hunter et al (61) highlighted the individual patient variability in 
  
 
103 
 
dose to the parotid glands; with some glands showing an increase in dose, and others a 
reduction in dose. In glands where a reduction in dose was noted, the contralateral 
gland received an increased dose; suggesting that rotational set up deviations 
contributed to alterations in dose delivery. Rotational set up deviations were not 
corrected for in their investigation. Set-up corrections in the craniocaudal, 
anteroposterior and lateral planes are regularly performed; however, in order to correct 
rotational set-up variations, a specialised couch is required (106).  
 
7.3.6 Frequency of Imaging and Adaptive Replanning 
 
The frequency of dosimetric evaluation in this investigation is similar to the study 
published by Schwartz et al (23), where 24 patients underwent daily in-room CT 
scanning with weekly dose calculation on contours created by deformable-image 
registration technique. All patients required at least one replan due to “CTV and normal 
tissues changes”.   However, underdosing of the CTV was not observed, suggesting that 
replanning was required due to excessive OAR dose.  By contrast, this investigation 
demonstrates inadequate PTV coverage in 80 % of the patient cohort (8 of the 10 
patients), requiring IMRT plan adaptation during the course of treatment. Plan 
adaptation was required due to inadequate PTV coverage in all cases, rather than 
excessive OAR dose. 
Other investigators (18,20,76) have reported lower rates of plan adaptations than what 
is reported in this investigation; however the frequency of CT scanning and dosimetric 
analysis in these reports is less than weekly.  Ahn et al (18); re-imaged at three time 
points during the treatment course; and demonstrated that 65 % of their patients (15 of 
23) required replanning, predominantly due to inadequate PTV coverage. Wang et al 
(76), undertook a single re-imaging at fraction 25, and reported that 50 % of unadapted 
plans were noncompliant for OAR dose criteria. Jensen et al (52) report that 21 % of 
their cohort required plan adaptation, however this decision was based on an 
assessment of differences in contour overlay, rather than a dosimetric evaluation. 
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7.3.7 Timing of Adaptive Replanning 
 
Significant changes in anatomy occurring in the first half of treatment have previously 
been reported (48), with greater volume loss occurring in the parotid and 
submandibular salivary glands during the first half of treatment compared to the second 
half. This has been discussed in greater detail in sections 2.3.1 and 2.3.2. Furthermore, 
section 2.5 discusses how significant dosimetric alterations to OARs, have been 
identified early in the 35 fraction radiation therapy course.  
Given the demonstration of significant dosimetric alterations occurring early in the 
treatment course, with subsequent benefit of plan adaptations; many authors have 
recommended that an ART protocol should be implementing repeat imaging and plan 
adaptations in the first half of treatment (Section 2.8.3, Table 2.6) (18,20,25,48,59,86). 
Schwartz et al (23), who performed weekly dose calculations, report  that the median 
timing of first replan for their cohort was at fraction 16. Bhide et al (11) demonstrated 
significant changes in PTV coverage by week two of radiotherapy; however their patient 
cohort had also undergone induction chemotherapy, which would have affected tumour 
volume prior to commencement of radiation therapy.  
In this patient cohort, adaptive replanning was required early in the 35 fraction course 
of radiation therapy. 41 % of replanning events occurred at or before fraction 10; and 
more than half events had occurred by fraction 15. All first IMRT plan adaptations and 
half of the second plan adaptations had occurred by fraction 15. This suggests that 
inadequate IMRT plan dosimetry can occur early and due to changes too subtle to be 
detected by assessing mask fit.  However, there was also a need to perform plan 
adaptations till the very end of the treatment, with four plan adaptations (18 % of the 
total) required at fraction 30. 
 
7.3.8 Strengths of this Investigation 
 
The strengths of this investigation lie in the weekly planning CT scans, which allowed for 
regular assessment of the “actual” dose delivery as anatomical changes occurred. DVH 
parameters were prospectively set to indicate unacceptable dose delivery and as a 
trigger for plan adaptation. This permitted a truly adaptive approach to be implemented 
as patients were treated with a re-optimised plan, within 48 hours of the CT scan 
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demonstrating unacceptable dose delivery. An advantage of using standard fan beam CT 
is ease of dose calculation (92). Cone beam CT may be subject to a number of image 
artefacts that complicate accurate dose calculation (i.e. reduced field of view, scatter 
causing unstable Hounsfield Unit numbers, ring artefacts etc.) (107). 
An additional strength of this study is that manual contour delineation of all structures 
was performed, which currently is superior to the use of contour propagation via 
deformable image registration and autosegmentation software, especially for the GTV 
and CTV volumes. The use of automated contour propagation is appealing, as it can save 
time compared to manual contour delineation. Publications report a 30 to  40 % time 
saving in the contour delineation process using an Atlas Based Autosegmentation 
technique (108–110). This can be significant, especially as contour delineation in HNC 
can take up to 44 to 144 minutes on average (80,81,95); and longer for less experienced 
physicians. However, the use of automated contour propagation has several limitations. 
Its accuracy is very dependent on the similarities between the atlas used and the 
anatomy of the patients.  The automatically propagated contours are limited by the fact 
that repeat imaging generally does not use i.v. contrast. Additional limitations arise from 
the presence of dental artefacts, as well as the deformations in normal anatomy in 
patients, due to tumour or nodal enlargement. Automatically propagated contours 
usually require editing by the physician, in order to be suitable for planning use 
(97,108,109,111). GTV and CTV volumes (both primary tumour and nodal) need greater 
correction than OARs. Some OARs require little or no editing, for example the spinal 
cord and mandible; others require a degree of editing especially where there is less 
contrast between the soft tissue planes, for example the submandibular glands 
(108,111,112).  
 
 7.3.9 Limitations of this Investigation 
 
Despite having a large number of CT scans to evaluate (total 84); with a patient cohort of 
10, this is considered an exploratory investigation of an ART protocol. Comparison of 
the results presented in this thesis with other published literature or by performing a 
larger study is recommended when instituting an ART protocol for HNC treatment. 
Weekly imaging and analysis is a resource intensive process, therefore other 
investigators undertake either a protocol with larger patient numbers and a lower 
frequency of imaging; or smaller patient numbers if weekly imaging is performed. Other 
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prospective reports, incorporating weekly imaging, have enrolled 11 to 20 patients 
(23,25,41,59,77). 
Additionally, the weekly CT scans were non-contrast scans, to reduce patient 
inconvenience and risk. Whilst the use of i.v. contrast for the weekly CT scans would 
have been gold standard for weekly comparison, the potential risks associated with 
weekly i.v. contrast administration had to be taken into account for this protocol. 
However, contours were able to be delineated quite confidently on the non-contrast CT 
scans, as the original planning CT scan (with i.v. contrast) was referred to, assisting with 
consistent contour delineation. 
A formal assessment of intraobserver variability was not undertaken for this 
investigation. However, intraobserver variability was minimised by adhering strictly to 
anatomical boundaries and the use of published contouring guidelines when contouring. 
Additionally, notes were made when contouring on the planning CT scan, to ensure 
consistency across contouring on the weekly CT scans. Only two authors of the 
numerous papers cited in this thesis have performed a formal assessment of 
intraobserver variability (11,22); both reported that intraobserver variability was non-
significant. Ricchetti et al (22) reported that the greatest intraobserver variability was 
seen for the submandibular glands and larynx in their study.  Interobserver variability 
may have affected the volume changes observed in this investigation and should be 
considered when interpreting the data. 
A further limitation is that some of the data analysis was performed retrospectively, 
some years after the initial analysis and patient treatment. This meant that some 
analysis was no longer possible to perform, for example NTCP modelling, due to 
technical issues regarding the restoration of patient data onto the treatment planning 
system. One patient’s data were also lost, so the additional retrospective analysis is 
missing some data points.  
 
7.3.10 Recommendations as a Result of this Investigation 
 
The findings of this investigation result in some recommendations being made for ART 
implementation. 
i. An ART protocol should be implemented for all HNC patients undergoing 
definitive radiation therapy; 80 % of the patient cohort required one or more 
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plan adaptations and no recommendation can be made for selecting patients at 
highest risk for inadequate dose delivery. 
ii. Imaging and assessment of dose delivery should be undertaken at multiple time 
points during the course of RT; as often as departmental resources allow.  
iii. Patients with a large initial volume of nodal disease should be considered for 
more frequent imaging and plan assessment. 
iv. The first repeat imaging and plan assessment, to new contoured volumes, 
should occur early in the treatment course, as early as fraction 5 or 10.  
v. Repeat imaging and plan assessment should also be undertaken later in the 
course of RT, e.g. at fraction 25, as suboptimal dose delivery can still occur at 
this stage. 
vi. Good communication and teamwork are essential in streamlining the ART 
process and ensuring a rapid turnaround time for a new treatment plan to be 
delivered. 
 
7.3.11 Future Research Directions 
 
As a result of this investigation, suggestions for future investigations to build on this 
work are made. These include the investigation of: 
i. Other imaging modalities to assess plan adequacy and a need to perform plan 
adaptation, e.g. Cone Beam CT imaging, MRI imaging. 
ii. How autosegmentation software could be best employed to increase efficiency in 
contour delineation. 
iii. The best process for delineating shrinking target volumes in the neck, in order to 
avoid undertreating microscopic disease as tumour shrinkage occurs. 
iv. The impact of an ART protocol on clinical outcomes, e.g. xerostomia, quality of 
life and tumour control, in larger prospective studies. 
v. Factors which could predict the need for plan adaptation. The PG-SGA should be 
considered for larger prospective investigations, as one of its components is 
patient weight. 
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7.3.12 A Cone Beam CT Imaging Protocol 
 
CBCTs are in widespread use for head and neck cancer radiotherapy, to improve the 
accuracy of dose delivery, via daily online verification of patient positioning. 
Additionally CBCT imaging can be utilised for dose calculations of both target volumes 
(113–115) and OARs (21,60,113–115) during the course of RT; to assess changes in 
dose delivery from the initial planning CT. The use of CBCT scans in ART has some 
advantages: 
i. Minimal additional “on-table” time to acquire a CBCT. 
ii. The patient is already in the treatment position, and this reduces variability in 
patient positioning, compared to the repositioning required to obtain a 
conventional planning CT scan. 
iii. Dose calculation can be performed on CBCT image sets by applying appropriate 
corrections for Hounsfield Units. 
iv. The validity of automated software approaches to delineation and planning to 
achieve daily ART can be assessed and implemented. 
 
However, routine CBCT use for the assessment of patient anatomy and dose delivery is 
currently limited for several reasons. Firstly, the quality of CBCT images, in terms of soft 
tissue definition, is not sufficient for the accurate delineation of certain contours, for 
example the GTV and at-risk nodal areas (21,116,117). Although some investigators 
have reported that CBCT images are of sufficient quality to outline many structures in 
the H+N (21,113,118) for dose evaluation purposes, conventional planning CTs are still 
required when undertaking a treatment plan adaptation. Researchers at one unit have 
described a protocol utilising high dose CBCT imaging for dosimetric evaluation, due to 
the superior soft tissue detail when compared to the lower dose CBCT used for daily 
IGRT (21). Secondly, the field length for the CBCT is shorter than conventional planning 
CT, and therefore the full head and neck field cannot be imaged in a single CBCT. 
However, some centres have developed in-house software to combine two CBCTs to 
allow for a more thorough assessment of the patient anatomy and dose delivery 
(113,115). 
Whilst there are multiple reports of phantom studies comparing the dose calculations 
between CBCT and conventional planning CT, there are few comparisons in patients. In 
two studies comparing dose calculations in both phantoms and HNC patients, the CBCT 
  
 
109 
 
and conventional planning CT dose calculations varied by +/- 3 % (replicating what has 
been reported in phantom studies); however it is worth noting that the number of 
patients investigated in each study was two (113,119). This may currently limit the use 
of CBCT images for dose calculation. 
A retrospective study compared the concordance of contours created manually by the 
radiation oncologist on the conventional planning CT (obtained after the delivery of 40 
or 50 Gy) with the contours generated via a deformable image registration method on 
the CBCT obtained at the same time, use Dice Similarity Coefficient (DSC) analysis (118). 
Good concordance was demonstrated for the mandible and parotid glands (Median DSC 
0.8), whereas the nodal GTV was not as reliably replicated on the CBCT (Median DSC 
0.55) due to poor image resolution. 
As a result of this investigation, a protocol concept for evaluating the use of CBCT images 
in an ART protocol is in development. This protocol aims to build on prior knowledge of 
the use of CBCT in ART for H+N cancer. It will assess the feasibility of CBCT to determine 
RT plan quality compared to conventional planning CT scan. A comprehensive 
comparison of the volumes of the contours generated on the 2 image sets will add 
valuable information to the already published literature. In addition, a comparison of the 
time taken to assess RT plan quality for both CTs will provide a useful insight into the 
likely benefit in terms of resource use. This concept outline for this proposed study is 
attached as Appendix 3. 
 
7.4 Conclusions 
 
Due to the small cohort of patients, this investigation is regarded as an exploratory 
study. However, the findings add to the literature supporting the use of an ART protocol 
for HNC patients. Inadequate PTV coverage was demonstrated in 80 % of the patient 
cohort, requiring one or more adaptations of the IMRT plan during the course of 
treatment. In all cases, IMRT plan adaptation was required due to inadequate PTV 
coverage, rather than excessive Organ at Risk dose. Adaptation of the IMRT plan led to a 
significant improvement in PTV coverage, as well as reduced dose to the parotid glands 
(upon further plan re-optimisation) and spinal cord. Whilst a benefit of ART in terms of 
dose distribution to the tumour volumes, parotid glands and spinal cord has been 
demonstrated in this investigation; larger prospective studies are required to establish 
whether a dosimetric benefit translates into an advantage in terms of clinical outcome.  
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This investigation found that 41 % of replanning events occurred at or before fraction 
10; all first IMRT plan adaptations and half of the second plan adaptations had occurred 
by fraction 15. This adds evidence to other publications which demonstrate that 
inadequate IMRT plan dosimetry can occur early in the treatment course. An ART 
strategy triggered due to notable weight loss or a loose fitting face mask would provide 
adaptation much later than when dosimetrically required. The first repeat imaging and 
plan assessment, to new contoured volumes, should occur early in the treatment course, 
as early as fraction five or 10.  
Significant resources are required to implement an ART strategy for all HNC patients. 
Identifying those patients who would most benefit from ART remains challenging. 
Larger scale prospective investigations would be useful to identify reliable surrogate 
measures that would trigger plan adaption; hence directing resources where they are 
most required. The PG-SGA score, a nutritional tool validated in the oncology setting, 
should be further evaluated in this context. Streamlining the ART process may also 
result in a more practical ART strategy, and should be investigated further; for example 
the utilization of dose calculation on Cone Beam CT Imaging, and in particular 
automated contour propagation. Ultimately, an ART strategy which improves plan 
dosimetry would only be worthwhile if it results in an improvement in patient clinical 
outcomes.   
This investigation presents a morphologically guided approach to ART in patients with 
Head and Neck Cancer. Whilst weekly imaging with high quality simulation CT and plan 
optimisation (when required) resulted in a significant workload increase, it is envisaged 
that the work undertaken will enable a similar approach to be taken in a more 
streamlined fashion; using enhanced cone beam CT, automated contour propagation and 
auto-planning tools. 
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Appendix 1  
Patient Generated Subjective Global Assessment (PG-
SGA) Worksheet 
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Appendix 2  
ECOG Performance Status Categories  
 
ECOG Performance Status Scale 
Grade Descriptions 
0 
Normal activity.  Fully active, able to carry on all pre-disease performance without 
restriction. 
1 
Symptoms, but ambulatory.  Restricted in physically strenuous activity, but 
ambulatory and able to carry out work of a light or sedentary nature (e.g., light 
housework, office work). 
2 
In bed <50% of the time.  Ambulatory and capable of all self-care, but unable to 
carry out any work activities.  Up and about more than 50% of waking hours. 
3 
In bed >50% of the time.  Capable of only limited self-care, confined to bed or 
chair more than 50% of waking hours. 
4 
100% bedridden.  Completely disabled.  Cannot carry on any self-care.  Totally 
confined to bed or chair. 
5 Dead. 
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Appendix 3  
Concept Outline for Future Investigation  
 
Feasibility of Cone Beam CT use for adaptive radiotherapy in Intensity 
Modulated Radiotherapy (IMRT) for Head and Neck Cancer (HNC). 
  
Background + Rationale:  
IMRT for HNC is planned using a planning CT image dataset which is obtained prior to 
treatment. Patient anatomy changes during radiotherapy (RT), due to weight loss and 
tumour mass change. Hence the planned dose distribution is not actually delivered, with 
potential for tumour underdosing and critical structure overdosing. Adaptive RT (ART) 
modifies the treatment plan during RT to account for anatomical changes, for which the 
“gold standard” identification method is a repeat conventional planning CT scan once 
(or more) during the course of RT. However, resource implications limit its widespread 
implementation. With the availability of cone beam CT (CBCT), there is potential for its 
use in an ART process, allowing for a convenient and objective assessment of RT plan 
quality, without the need to perform additional conventional planning CTs during the 
treatment course.  
 
Aim: To determine the feasibility of using CBCT to assess RT plan quality. 
Objectives: 
Primary- To measure the proportion of patients whose CBCT scans are adequate for an 
assessment of RT plan quality.  
Secondary-  
i. To compare the time taken to contour relevant organs and evaluate the 
radiotherapy plan using CBCT and conventional planning CT image sets.  
ii. To compare the dose distributions obtained using CBCT and conventional 
planning CT images. 
 
Hypotheses: 
i. The true rate of patients with adequate CBCT scans will be >95%, indicating that 
further investigation into the use of CBCT in an ART protocol is worthy of 
undertaking.  
ii. The process of evaluating the RT plan on CBCT images will take less time than 
using conventional planning CT. 
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iii. The fan beam CT and CBCT both give the same relative difference in dose from 
the original planning CT 
 
Outcomes and measures:  
Primary outcome- The assessment of RT plan quality using CBCT in a patient will be 
deemed to be “inadequate” if one or more scans have one or more of the following 
characteristics: 
a. Image quality too poor to identify and contour the Clinical Target Volumes 
(CTVs). 
b. Difference in volumes of the Regions of Interest between the CBCT and 
conventional planning CT to be greater than 5%. 
c. The DSC comparison for the corresponding contours is less than 0.8 for parotid 
glands, mandible and spinal canal; and less than 0.75 for CTV. 
Secondary outcomes- 
i. Time (in minutes) to generate contours and perform an assessment of the RT 
plan quality on the CBCT and conventional planning CT. 
ii. Measurement of the V95 for the Planning Target Volumes (PTVs); i.e. the volume 
of the PTV receiving ≥95% of the prescribed dose. 
iii. Measurement of the parotid gland V26 (volume receiving ≥26Gy) and mean 
dose. 
iv. Measurement of spinal cord Dmax (Maximum dose). 
 
Study population:  
Patients undergoing primary chemo-RT for mucosal HNC. Patients must be over 18 
years of age and had no prior RT or surgery to the Head and Neck region. 
Study design: Single arm feasibility study. 
 
Intervention:   
All patients undergo high dose CBCT whilst on treatment bed and conventional planning 
CT (in CT simulation room) in the treatment position every 10 fractions during RT. 
Patient weight and PG-SGA score (indicating nutritional status) will be collected weekly. 
 
Study procedure: 
A planning CT scan undertaken for treatment planning. At Fractions 1,11,21,31, a high 
dose CBCT scan will be performed before treatment is delivered. Patients will have a 
non-contrast conventional planning CT scan within 24 hours of the CBCT scan. Patients 
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will be assessed weekly by a dietician, to record weight and PG-SGA score. Contours for 
tumour volume and organs at risk will be performed by the chief investigator. The 
conventional planning CT datasets will be assessed the same day for plan adequacy 
(tumour coverage and critical OAR dose), with reoptimisation of the IMRT plan if 
required. The CBCT datasets will be registered, contoured by the chief investigator and 
assessed retrospectively. 
 
Statistical considerations: 
Sample size: 19 patients with evaluable data.  
Using a 1-stage, single arm binomial design, a total of 19 participants with complete data 
will provide 1-sided type 1 and type 2 error rates of 10% for distinguishing the 
observed frequency of adequate CBCT from true rates of 95% (worthy of pursuit), 
versus 75% (not worthy of pursuit). CBCT will be considered worthy of pursuit if 16 of 
the 19 participants (84%) or more have adequate CBCT, but not if 15 of the 19 (79%) or 
fewer have adequate CBCT. 
 
Feasibility: 
Two patients at a time will be recruited to the investigation, due to the resources 
required. 
Timeframe: Accrual of 14 patients a year, therefore 1.5 years to complete accrual. 
 
Significance:  
If CBCT scans are considered to be adequate to assess RT plan quality, their use could 
result in a swifter and more practical ART process, by ensuring repeat conventional 
planning CT and replanning occurs only in those patients who require IMRT plan 
optimization. This would encourage more widespread adaptation of an ART protocol in 
this patient population. Future investigations could look at the most practical frequency 
of performing CBCT scans and the use of automated contouring software to streamline 
the ART process further. 
 
Risks:  
There is additional radiation exposure to the patient of 0.2cGy per conventional 
planning CT scan, leading to a total of 8cGy in total. The CBCT scan delivers 0.2 to 2cGy 
per scan, with a total of 0.8 to 4cGy. This compares to the daily additional radiation 
exposure of 0.02 to 0.04cGy for the current Electronic Portal Imaging method. To put 
into perspective, the total delivered treatment dose for RT is 7000cGy. 
